This is the peer reviewed version of the following article: Abdalla, MA, Shah, N, Deshmukh, H, et al. Impact of pharmacological interventions on anthropometric indices in women with polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled trials. Clinical Endocrinology. 2022; 1-23., which has been published in final form at doi.org/10.1111/cen.14663. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for self-archiving.

6 Impact of pharmacological interventions on anthropometric indices in women with polycystic ovary

7 syndrome: a systematic review and meta-analysis of randomised controlled trials

- 8 Running title: pharmacological interventions in PCOS
- 9 Mohammed Altigani Abdalla¹, Najeeb Shah¹, Harshal Deshmukh¹, Amirhossein Sahebkar^{2,3,4},Linda
- 10 Östlundh ⁵, Rami H. Al-Rifai⁶, Stephen L. Atkin⁷, Thozhukat Sathyapalan¹
- ¹Academic Diabetes, Endocrinology and Metabolism. University of Hull, Hull York Medical School
- 12 (HYMS), Hull, UK
- ²Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical
- 14 Sciences, Mashhad, Iran
- 15 ³Applied Biomedical Research Center, Pharmaceutical Technology Institute, Mashhad University of
- 16 Medical Sciences, Mashhad, Iran
- 17 ⁴School of Medicine, the University of Western Australia, Perth, Australia
- 18 ⁵College of Medicine and Health Sciences, the National Medical Library, United Arab Emirates
- 19 University, United Arab Emirates
- ⁶College of Medicine and Health Sciences, Institute of Public Health, United Arab Emirates University,
- 21 Al Ain, United Arab Emirates
- ⁷School of Postgraduate Studies and Research, RCSI Medical University of Bahrain, Kingdom of
 Bahrain
- 24 Correspondence: Professor Thozhukat Sathyapalan

25	Department of Academic Diabetes, Endocrinology and Metabolism, Hull York Medical School,
26	University of Hull.
27	Email: <u>Thozhukat.Sathyapalan@hyms.ac.uk</u>
28	Keywords: polycystic ovary syndrome (PCOS); BMI; WC; WHR; body weight; pharmacological therapy.
29	PROSPERO registration No: CRD42020178783
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	

43 Abstract

44 Context: Polycystic ovary syndrome (PCOS) is a heterogeneous condition affecting women of
 45 reproductive age and is associated with increased body weight.

46 **Objective:** To review the literature on the effect of different pharmacological interventions on the
47 anthropometric indices in women with PCOS.

48 Data sources: We searched PubMed, MEDLINE, Scopus, Embase, Cochrane library and the Web of
49 Science in April 2020 with an update in PubMed in March 2021.

Study selection: The study followed the Preferred Reporting Items for Systematic reviews and Meta Analyses (PRISMA)2020.

52 Data extraction: Reviewers extracted data and assessed the risk of bias using the Cochrane risk of bias
53 tool.

54 Results: 80 RCTs were included in the meta-analysis. Metformin vs placebo showed significant reduction in the mean body weight (MD: -3.13 kgs; 95% CI:- 5.33,-0.93, I²= 5%) and the mean body 55 mass index (BMI) (MD: -0.75 kg/m²; 95% CI: -1.15, -0.36, l^2 = 0%). There was a significant reduction in 56 57 the mean BMI with *orlistat vs placebo* (MD: -1.33 kg/m²; 95% CI: -2.16 -0.66, l^2 = 0.0%), acarbose vs metformin (MD: -1.26 kg/m²; 95% CI: -2.13, -0.38, l^2 = 0%), and metformin vs pioglitazone (MD: -0.91) 58 59 kg/m²; 95% CI: -1.62, -0.19, I²= 0%). A significant increase in the mean BMI was also observed in pioglitazone vs placebo (MD: +2.59 kg/m²; 95% CI: 1.78, 3.38, I²= 0%) and in rosiglitazone vs metformin 60 (MD: +0.80 kg/m²; 95% CI: 0.32, 1.27, I²= 3%). There was a significant reduction in the mean waist 61 62 circumference (WC) with metformin vs placebo (MD: -1.21 cm; 95% CI: -3.71-1.29, l^2 = 0%) while a 63 significant increase in the mean WC with *pioglitazone vs placebo* (MD: +5.45 cm; 95% CI: 2.18, 8.71, 64 $l^2 = 0\%$).

65 Conclusion: Pharmacological interventions including metformin, sitagliptin, pioglitazone, rosiglitazone
 66 orlistat and acarbose have significant effects on the anthropometric indices in women with PCOS.

67 Introduction

68 Polycystic ovary syndrome (PCOS) is a heterogeneous and complex endocrine disorder affecting women of reproductive age, with a prevalence ranging from 8% to 13 % ^{1,2}. PCOS is characterised by 69 70 both clinical and biochemical evidence of excess androgen levels (manifested as acne and hirsutism), 71 menstrual irregularities and sonographic polycystic ovarian morphology³. Metabolic disorders such as 72 insulin resistance (IR) and impaired glucose tolerance are common in women with PCOS, leading to an 73 increased risk of type 2 diabetes mellitus (T2DM)⁴. Moreover, PCOS predisposes to a range of other 74 complications including infertility, increased body weight, increased risk of cardiovascular disease 75 (CVD) and endometrial cancer⁵⁻⁷.

76 Increased body weight is a prominent feature of PCOS and around 50% of women with PCOS are either 77 overweight or obese⁸. Obesity exacerbates PCOS features such as excessive hair growth, infertility and pregnancy complications, aggravates IR, which culminates in an increased metabolic risk associated 78 79 with PCOS⁹. Therapeutic approaches including lifestyle modifications through dietary interventions and physical activity are the cornerstone in the management of PCOS¹⁰. There are also differing 80 81 pharmacotherapeutic interventions including insulin sensitisers (metformin and thiazolidinediones) that improve IR and peripheral glucose uptake ^{11,12}. However, these therapeutic options are primarily 82 83 licensed to treat other conditions such as T2DM and their effectiveness in PCOS remains unclear in 84 the literature. There are also significant gaps between the available evidence and the evidence-based 85 treatment options³. This might often lead to the delay in offering satisfactory treatment options and 86 the clinical inertia around treating PCOS³. Therefore, this systematic review and meta-analysis aimed 87 to evaluate and analyse the available evidence on the effectiveness of different therapeutic options 88 used to treat PCOS in improving anthropometric outcomes.

89 Methods

90 **Protocol and registration**

91 This systematic review and meta-analysis were prospectively registered in the PROSPERO 92 international prospective register of systematic reviews (CRD42020178783) and is reported according 93 to the 2020 Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) 94 statement¹³.

95 Eligibility criteria

We included only randomised controlled trials (RCTs). The RCTs included in the systematic review were defined based on the PICO (population, intervention, comparator, and outcome) elements. The inclusion criteria are presented in Table 1. Briefly, only RCTs recruited women of reproductive age (≥ 18 years) diagnosed with PCOS were eligible. RCTs were included regardless of the design (openlabelled, double-blinded, and within-subject crossover) and randomisation methodology. Also, RCTs needed to have reported a comparison of at least one pharmacological agent with placebo or various combinations of pharmacological agents.

103 Literature search

104 A systematic and comprehensive literature search was conducted in six biomedical databases: 105 PubMed, EMBASE, MEDLINE, Scopus, Cochrane Library (CENTRAL) and Web of Science, in April 2020 106 with an update in PubMed in March 2021 (L.Ö). The medical database PubMed was used to develop a 107 preliminary search strategy. Search terms were selected by experts in the field of the subject (T.S & 108 M.A) in close collaboration with a medical librarian specialised in systematic reviews (L.Ö). All terms 109 were searched in a combination of title, abstract and Medical Subject Headings (MeSH) for the best possible literature retrieval. A filter for English language was applied. The search string developed in 110 111 PubMed were later used to search in all selected electronic databases. A separate search for grey,

unpublished literature and clinical trials was performed in March 2021 including Open Grey Clinical
Trials.gov and in the European Union Drug Regulating Authorities Clinical Trials Database (EudraCT).
The full search strategy including results, notes and search technical specifications for all databases
and grey sources is available as a supplementary material.

All records found in the literature search were uploaded to Covidence software(<u>www.covidence.org</u>)¹⁴ for blinded screening. Full-text review and data extraction were performed after automatic removal of the duplicate records in the software. Selected references were then uploaded to the EndNote software for reference management¹⁵. Finally, the reference lists of all included studies as well as systematic reviews and meta-analyses found in the literature search were screened by hand for additional undetected studies (M.A & N.S). Cabell's Predatory Report ¹⁶ was used to verify that none of the selected studies were published in potential predatory journals.

123 Study selection

Two reviewers (M.A, & N.S) conducted the initial screening by independently assessing titles and 124 abstracts for eligibility considering the inclusion/exclusion criteria. Full text assessment of the 125 126 potentially eligible studies was undertaken blindly by both reviewers. Any disagreements between 127 reviewers about the inclusion were resolved by consensus (M.A, N.S) using covidence blinded conflict resolving function (<u>www.covidence.org</u>)¹⁴.Non-pharmacological interventions and observational 128 129 studies were excluded. Where duplicate publications for the same study were identified, the most 130 recent version of the study was selected. The process of study identification and selection was 131 performed independently by two reviewers. The study selection process is presented in Figure 1 132 following the PRISMA guidelines¹³.

133 Data extraction

Two independent reviewers (M.A and N.S) extracted information on the country of the RCTs, name of
the author, year of publications, design of the intervention, type of the interventions and comparators,

number of participants and baseline characteristics of the participants, duration of the RCTs, and the
 measured anthropometric outcomes reported including body weight, body mass index (BMI), waist
 circumference (WC), and waist to hip ratio (WHR).

139 Risk of bias assessment in the included studies

140 The Cochrane collaboration's tool for assessing risk of bias (RoB) was used as recommended by Higgins 141 et al¹⁷. Six domains including (selection bias, performance bias, detection bias, attrition bias, reporting 142 bias and other bias) were assessed. Two independent reviewers (M.A and N.S) assessed the RoB for 143 each study, and a third reviewer (S.T) mediated any conflict between reviewers. The recommendations from the Cochrane handbook¹⁸ were followed and any RoB was graded as either 144 145 'high RoB', 'low RoB', or 'unclear RoB' Figure 1, supplementary materials. The proportion of studies regarded as either with 'high RoB', 'low RoB', or 'unclear RoB' for each specific RoB domain was 146 147 calculated and reported Figure 1, supplementary materials.

148 **GRADE scoring**

The strength of the evidence for each desired outcome (body weight, BMI, WC, and WHR) was assessed using recommendations from the Grading of Recommendations, Assessments, Development and Evaluation (GRADE) system¹⁹. GRADEpro GDT software was used to grade the quality of each outcome and to produce "Summary of findings Table" Table 1, supplementary materials.

153 Data analysis and evidence synthesis

When quantitative data on the impact of the intervention (mean value) on a specific outcome from at least two independent trials were available, the pooled effect estimates (mean difference) and its 95% confidence intervals (95% CI) were quantified using the random-effects model as recommended by the *Cochrane handbook*¹⁸. To conduct the meta-analysis for the continues outcomes, we assumed data were normally distributed. Extremely skewed data or data reported as range were excluded from the 159 meta-analysis. Means and standard deviation (SD) for both pre and post-intervention values and 160 changes from baseline scores were combined for the meta-analysis. For data presented as standard 161 error (SE), Cls, *p*-values, and *t* values, the RevMan calculator was used when necessary to convert them 162 into means and SD. Mean difference (MD) was used when same continuous data presented using the 163 same scales across the trials. Where units of measurements were varied, scales were converted to the 164 most common measures. For trials with more than one intervention arm, data from all arms were combined using the method recommended in the Cochrane Handbook¹⁸. Post-intervention scores and 165 166 data from crossover trials were used from the last point the trials were reported.

167 Assessment of heterogeneity

Heterogeneity for each result of the outcomes across the trials was assessed using the squared (l^2) statistics. A statistically significant heterogeneity (observed l^2 %) was determined by visually examined forest plots for no substantial or little overlapping of the confidence intervals (CIs) of the results across the studied. For substantial heterogeneity, the source was investigated by removing the study that represented the largest effect from the analysis and the l^2 was re-evaluated. If heterogeneity was still not resolved, assessment of the population groups for similarities in the baseline characteristics and subgroup analyses were performed.

175 Subgroup analysis

Where data from more than two trials were present, subgroup analysis was conducted. Subgroup analysis was performed on the characteristics of the interventions including dosages/mg, frequency of administration (one/day [QD], twice/ day [BID] and trice/day [tds]), and duration of the interventions (weeks/months). Outcome data were divided by subgroups, and the subtotal summary of results were presented and reported quantitatively.

181 Trial data were pooled, and meta-analysis was performed using the Review Manager software182 (RevMan 5.4, The Cochrane collaboration).

183 Results

In total, 6,326 records were identified, of which 3,186 studies were screened for eligibility based on titles and abstracts after removing duplicates. A total of 814 full-text articles were retrieved for detailed assessment for eligibility, of which 80 RCTs were found eligible and included in this study (Figure 1). No additional, eligible studies were identified in the hand screening of the included papers.

188 characteristics of the included RCTs

The 80 RCTs were published between 2000 and 2020 and included (4,028 participants both PCOS and control) that met the inclusion criteria and were included in the meta-analysis. Forty-two trials²⁰⁻⁶¹ diagnosed PCOS based on the Rotterdam 2003 criteria⁶², ten trials^{35,63-72} used the National Institute of Health 1990 (NIH, NICHD) criteria, one trial⁷³ used the Androgen Excess Society 2006 (AES) criteria⁷⁴, and no diagnostic criteria were specified for the reminder of the trials (Table 2).

194 Interventions and comparisons details

195 effect metformin Twenty-one RCTs (26.3%) assessed the of compared with placebo^{20,26,31,36,37,39,42,46,47,50,54,57,59,75-83}. Six RCTs (7.5%) compared metformin with pioglitazone^{23,53,61,84-} 196 ⁸⁶. Two RCTs (2.5%) evaluated liraglutide compared with metformin^{69,87}. Five RCTs (6.3%) examined 197 pioglitazone compared with placebo^{21,63,88-90}. Nine RCTs (11.3%) compared rosiglitazone with 198 metformin^{22,33,38,41,44,58,91-93}. Three RCTs (3.8 %) examined liraglutide compared to liraglutide added to 199 200 metformin^{34,35,71}.Three RCTs (3.8%) compared orlistat with metformin^{23,30,94}. Two RCTs (2.5%) 201 compared sitagliptin added to metformin with metformin alone^{28,95}. Two RCTs (2.5%) evaluated sitagliptin with placebo^{24,29}. Three RCTs (3.8 %) assessed exenatide compared to metformin^{27,43,60}. Two 202 RCTs (2.5%,) compared orlistat with placebo^{25,45}. Two RCTs (2.5%) compared acarbose versus 203 placebo^{96,97}.Three RCTs (3.8%) compared acarbose to metformin^{51,67,72}. Two RCTs (2.5%) compared 204 saxagliptin alone and with metformin plus saxagliptin ^{55,65}. Two RCTs (2.5%) compared metformin with 205 simvastatin^{68,98}. Two RCTs (2.5%) compared metformin with NAC^{32,49}. Two RCTs (2.5%) examined 206

atorvastatin with placebo⁹⁹. Three RCTs (3.8%) compared spironolactone and placebo^{48,64,66}. Five RCTs
 (6.3%) assessed rosiglitazone with placebo^{40,73,100-102}(Table 2).

209 Outcomes measured

All RCTs assessed the outcomes at baseline and post-intervention at various follow up times. Thirtyone trials^{22,26,30,31,34,35,38,40-43,46,53,54,56,59,60,69,71,73,77,81,84-87,94,100,103} reported on changes in body weight.
Seventy-nine RCTs reported on changes in BMI as the primary outcome ^{20-55,57-61,63-73,77-92,95-}
^{99,101,102}.Twenty-three RCTs reported on changes in WC^{31,34,35,41,46,53-56,58,63,65,69-71,78,84,87,90,91}. Thirty- four
RCTs reported on changes in WHR ^{20,31,39-43,46,50,54,58,60,63,73,76,78,82,84-86,88,89,102} (Table 2).

215 Risk of bias assessment

216 Risk of bias (RoB) for the included RCTs and the overall RoB are illustrated in Figure 1, supplementary 217 materials. Twenty-six RCTs were judged to have low RoB with regard to selection bias for using 218 appropriate methods to generate their sequences for randomisation and allocation concealment ^{20,27,28,32,36-38,40,46,50,57,64,65,67,68,72,78,80,83,85,86,95-97}. One trial ⁶³ was judged to have a high risk of selection 219 220 bias. Five trials were categorised as having an unclear RoB across all six assessed RoB domains due to insufficient information ^{47,49,53,59,90}. Due to the nature of the trials (open-label), thirty-five trials were 221 judged to have a high risk of performance bias^{20,22,23,25,27-31,33-35,41,43,44,55,60,61,64-66,69-71,76,85-87,94}. The 222 223 remainder of the trials were judged to have an unclear risk of performance bias due to a lack of a clear 224 statement about whether the outcome assessors were blinded to the participants allocation and 225 interventions. One trial was judged to have a high risk of reporting bias due to selective data reporting 76. 226

227 Effect of interventions on anthropometric outcomes

Results of the pharmaceutical medications compared with placebo presented in Figures 2-3 andcompared with other medications are shown in Table 3.

230 Body weight

234

231 Metformin versus placebo

In four RCTs, metformin 1500 mg once a day (QD) significantly reduced the mean body weight (mean

233 difference (MD): -8.47 kgs; 95% CI: -13.50-3.98). In two RCTs compared placebo, metformin 850 mg

235 95% CI: -10.15 - 4.46 kgs). In four RCTs, metformin 2000 mg QD was associated with no significant

twice a day (BID) was associated with no significant change in the mean body weight (MD: -2.84 kgs;

change in the mean body weight (MD: -1.6 kgs; 95% CI: -4.08-0.84). Overall, regardless of the

administered dosage, metformin was associated with a significant reduction in the mean body weight

238 (MD: -3.13 kgs; 95% CI: - 5.33, -0.93, *I*²= 5%) compared with placebo. (Figure 2-A) (moderate grade

evidence, Table 1, supplementary materials).

240 <u>Metformin versus orlistat</u>

241 In three RCTs, Metformin 1500 mg QD for three months compared with orlistat 120 mg three times a

day (TDS) significantly reduced the mean body weight (MD: -3.28 kgs; 95% CI: -7.29-0.74, l^2 = 58%)

243 (Table 3); very-low grade evidence, Table 1, supplementary materials).

244 Metformin versus Rosiglitazone

Three RCTs compared metformin with rosiglitazone showed a significant increase in the mean body weight (MD: +1.95 kgs; 95% CI: 0.03-3.87, $l^2 = 3\%$) with rosiglitazone. This significant increase to the mean body weight was mainly driven by the RCTs that administered 1500 mg/day of metformin compared to 4 mg/day of rosiglitazone for six months (MD: +3.19 kg; 95% CI; 0.65-5.73) (Table 3) (very low-grade evidence, Table 1, supplementary materials).

The meta-analysis showed that there was no difference in the mean body weight when rosiglitazone
 was compared with placebo (Figure 2-B). Similarly, no significant change in the mean body weight was

- seen when metformin alone or in combination with liraglutide was compared with other medications(liraglutide, pioglitazone, and exenatide) (Table 3).
- 254 Body Mass Index

255 Metformin versus placebo

256 In four RCTs, metformin 850 mg BID for six months was associated with no significant change in the 257 mean BMI (MD: -0.94 kg/m²; 95% CI: -2.31-0.47, $I^2=0\%$) compared with placebo. The pooled effect 258 estimates from 11 RCTs showed that metformin 1500 QD for three months was associated with a significant reduction in the mean BMI (MD: -0.80 kg/m²; 95% CI: -1.30, -0.31, l²= 0%). The pooled effect 259 260 estimates from two RCTs showed that metformin 1500 mg QD for six months associated with no 261 significant change in the mean BMI (MD: +0.34 kg/m²; 95% CI: -1.01- 1.68, *I*²= 0%). Individual studies 262 showed no significant change in the mean BMI to metformin 1700 mg QD for 12 months (MD: -0.20 kg/m²; 95% CI: -1.67-1.27), to metformin 1000 mg QD for 6 months (MD: -1.20 kg/m²; 95% CI: -4.09-263 1.69), and to metformin 850 mg BID for 36 months (MD: -0.80 kg/m²; 95% CI: -2.14-0.54) compared 264 to placebo. Whereas metformin 1500 mg QD for seven weeks was associated with a significant 265 266 reduction in the mean BMI (MD: -3.0 kg/m²; 95% CI: -5.11, -0.89). Overall, regardless of the dosage, 267 duration, and frequency per day, the pooled effect estimates from 21 RCTs included 1,280 (662 in the 268 intervention arm, 618 in the placebo arm) women with PCOS showed that metformin was associated with a significant reduction in the mean BMI (MD: -0.75 kg/m²; 95% CI: -1.15, -0.36, l^2 = 0%) (Figure 3-269 270 A) (moderate grade evidence, Table 1, supplementary materials).

271 Orlistat versus placebo

Orlistat 120 mg tds for six months in one RCT and for three months in another RCT significantly
 reduced the mean BMI (MD: -1.33 kg/m²; 95% CI: -2.16 -0.66, *I*²= 0.0%) compared with placebo. (Figure
 2-A, supplementary materials) (very low-grade evidence, Table 1, supplementary materials).

275 Acarbose versus Metformin

In one RCT acarbose 100 mg QD for three months was associated with a significant reduction in the mean BMI, while in two RCTs acarbose 300 mg QD for three months was associated with no significant change in the mean BMI. However, in the three RCTs, regardless of the dosage, frequency, and duration, acarbose showed a significant reduction in the mean BMI (MD: -1.26 kg/m²; 95% CI: -2.13, -0.38, $l^2 = 0\%$) (Table 3) (low grade evidence, Table 1, supplementary materials).

281 <u>Pioglitazone versus placebo</u>

The pooled effect estimate showed that there was a significant increase in the mean BMI between women received pioglitazone 45mg QD (MD: +3.33 kg/m²; 95% CI: 1.60- 5.06), and pioglitazone 30 mg QD (MD: +2.38 kg/m²; 95% CI; 1.48-3.28). However, regardless of the dosage, frequency, and duration, the mean BMI increased (MD: +2.59 kg/m²; 95% CI: 1.78-3.38, l^2 = 0%) in 56 women who received pioglitazone compared to 58 women who received placebo. (Figure 2-B) (low grade evidence, Table 1, supplementary materials).

288 <u>Metformin versus Pioglitazone</u>

Metformin 850 mg BID for six months, in two RCTs showed a significant reduction in the mean BMI by (MD: -1.07 kg/m²), whereas metformin 1500 mg QD for 3 months in four RCTs, showed no significant change in the mean BMI compared to women in the pioglitazone group. Overall, metformin at various dosages significantly reduced the mean BMI (MD: -0.91 kg/m²; 95% CI: -1.62-0.19) (Table 3) (very low grade evidence, Table 1, supplementary materials).

294 Metformin and Sitagliptin versus Metformin alone

In two RCTs, when Sitagliptin 100 mg added to metformin at different doses, a significant reduction in

- 296 the mean BMI (MD: -3.94 kg/m²; 95% CI: -7.81-0.08, l^2 = 0%) was observed (Table 3) (very low grade
- 297 evidence, Table 1, supplementary materials).

298 Exenatide versus metformin

In three RCTs, exenatide 10 ug showed a significant reduction in the mean BMI (MD: -0.85 kg/m²; 95% CI: -1.61-0.08, l^2 = 0%). when compared with Metformin 1000 mg QD. (Table 3) (very low grade evidence, Table 1, supplementary materials).

302 Rosiglitazone versus Metformin

Compared with rosiglitazone 4 mg QD, metformin 850 mg BID, metformin 1500 mg QD, metformin 1000 mg QD and metformin 2000 mg QD were associated with no significant change in the BMI. Overall effect, regardless of the dosage, frequency, and duration, in 10 RCTs that included 262 women with PCOS in the metformin arm compared with 258 women with PCOS in the rosiglitazone arm, rosiglitazone was associated with a significant increase in the mean BMI (MD: +0.80 kg/m²; 95% CI: 0.32-1.27, l^2 = 3.0%) (Table 3) (moderate grade evidence, Table 1, supplementary materials).

The meta-analysis showed that there was no difference in the mean BMI when rosiglitazone, sitagliptin, atorvastatin and acarbose were compared with placebo (Figure 2-C,D,E and F). Similarly, no significant change in the mean BMI was seen when metformin alone or in combination with liraglutide was compared with other medications (liraglutide, orlistat, spironolactone, saxagliptin, simvastatin, and NAC (Table 3).

314 Waist Circumference

315 <u>Pioglitazone versus placebo</u>

The pooled estimate showed that there was a significant increase in the mean WC when women received pioglitazone 45 mg QD for six months (MD: +6.60 cm; 95% CI: 2.78- 10.42), pioglitazone 30 mg QD for 6 months (MD: +2.70 cm; 95% CI: -6.94-12.34) and pioglitazone 30 mg QD for 4 months (MD: +2.0 cm; 95% CI: -6.33- 10.33). However, regardless of the dosage, frequency, and duration, the mean WC was significantly increased (MD: +5.45 cm; 95% CI: 2.18- 8.71, *I*²= 0%) in 37 women who received pioglitazone compared to 40 women who received placebo (Figure 3-A, supplementary
 materials) (very low grade evidence, Table 1, supplementary materials).

323 Metformin versus placebo

In one RCT, metformin 2000 mg QD was associated with no significant change in the mean WC (MD: +0.80 cm; 95% CI: -4.32-5.92) while in four RCTs, metformin 1500 mg QD for three months significantly reduced the mean WC (MD: -1.84 cm; 95% CI: -4.71-1.03) when compared with placebo. However, regardless of the dosage metformin insignificantly reduced the mean WC (MD: -1.21 cm; 95% CI: -3.71-1.29, l^2 = 0%). (Figure 3-B, supplementary materials) (moderate grade evidence, Table 1, supplementary materials).

The meta-analysis showed that there was no difference in the mean WC when metformin alone or in combination with liraglutide was compared with pioglitazone, liraglutide, rosiglitazone and saxagliptin (Table 3).

333 Waist to Hip Ratio

334 Rosiglitazone vs placebo

The meta-analysis showed that there was a significant reduction in the mean WHR when rosiglitazone was compared with placebo (MD: -0.08; 95%CI: -0.11-0.04, l^2 = 0%) (Figure 4-A, supplementary materials) (very low-grade evidence, Table 1, supplementary materials).

No difference in the mean WHR when metformin, pioglitazone, and orlistat were compared with placebo (Figure 4- B, C and D, supplementary materials). Similarly, no difference in the mean WHR was also observed when metformin was compared with pioglitazone, exenatide, rosiglitazone, spironolactone, and saxagliptin (Table 3).

343 Discussion

344 This systematic review summarises the up-to-date evidence supporting the pharmacological interventions used in the management of PCOS. To our knowledge, this is the first comprehensive 345 systematic review to report the effects of different pharmacological interventions on the 346 347 anthropometric outcomes of women with PCOS. When metformin was administered at various 348 therapeutic doses, there was a statistically significant reduction in the mean body weight, BMI and 349 WC compared with placebo. Such effects were also observed when metformin was compared with sitagliptin and acarbose. On the other hand, pioglitazone and rosiglitazone were associated with a 350 351 significant increase in the mean body weight, WC and BMI.

352 Anthropometric outcomes

353 Regarding the effect on body weight and BMI, significant beneficial changes were found with 354 metformin versus placebo. Subgroup analyses also indicated that significant reductions in body weight and BMI were noted with differing doses of metformin administered for short or long durations. These 355 findings are in line with the results from previous systematic reviews in which metformin was with 356 357 lifestyle modification or placebo ^{104,105}. The most recent meta-analysis¹⁰⁵ reported a large reduction in BMI (WMD = -1.25 kg/m^2 , 95% CI: -1.60, -0.91, p < 0.00001) following treatment with metformin. 358 Another meta-analysis¹⁰⁴ also reported a significant reduction in BMI (MD) -0.73 kg/m²,95% CI: -1.14, 359 360 -0.32, P = 0.0005) with metformin compared with lifestyle or placebo. Therefore, the results reported 361 here are in accord with others that metformin as monotherapy can significantly reduce weight and BMI in women with PCOS. In the present review, it was shown that metformin could also reduce BMI 362 363 when compared with pioglitazone, an observation that is consistent with a previous meta-analysis in 364 which BMI was increased with pioglitazone treatment to a large extent compared with metformin¹². Similarly, another systematic review compared the effect of pioglitazone versus metformin in PCOS 365 and showed a decreased effect with pioglitazone than with metformin in reducing BMI¹⁰⁶. We also 366 found a significant reduction in body weight with metformin administered at various doses compared 367

with rosiglitazone; however, there was no difference between metformin compared with eitherliraglutide or exenatide.

Another observation was a significant reduction in BMI with orlistat compared with placebo, which is in line with the findings of other groups ^{107,108}.Nevertheless, no reduction in BMI was seen for orlistat compared with metformin. Finally, a significant reduction of BMI was found with sitagliptin added to metformin versus metformin alone. Currently, due to the cardiovascular risk and other adverse effects associated with thiazolidinediones and the troublesome gastrointestinal adverse effects of orlistat, these medications are of limited use.

376 Results in the current study are in accord with many clinical trials of varying designs that have 377 evaluated the effects of differing pharmacological interventions on the body composition in patients 378 with T2DM. In an observational study of 51 newly diagnosed patients with T2DM, metformin 1g/day 379 for duration of 6 months was associated with a significant improvement in body composition when compared with placebo¹⁰⁹. A recent systematic review and meta-analysis evaluating the efficacy of 380 381 differing pharmacological interventions on adults with T2DM showed that body weight was either significantly reduced or maintained in treatment with metformin and DPP-4 inhibitors¹¹⁰. Another 382 383 meta-analysis of 15 RCTs evaluating the effects of pioglitazone on the glycaemic indices, lipid profiles, 384 BMI and body weight in T2DM reported a significant increase in body weight and BMI (WMD 1.755, 95% CI 0.674 to 2.837 and 1.145, 95% CI 0.389 to 1.901, respectively)¹¹¹. In an RCT of 676 newly 385 386 diagnosed patients with T2DM (343 in acarbose group and 333 in metformin group) that examined 387 the effect of metformin and acarbose on WHR, it was reported that a significant reduction in WHR in both groups occurred after 25 weeks (acarbose: -0.015, 95% CI: -0.018 to -0.012, *P* < 0.001; metformin: 388 389 -0.013, 95%CI: -0.016 to -0.010, P < 0.001)¹¹².

This study followed a comprehensive and systematic search of relevant databases and grey sources that only included RCTs. To minimise the risk of bias, all observational studies and non-randomised clinical trials were excluded.

To the authors' knowledge, this study is the most comprehensive and up-to-date systematic review and meta-analysis on the impact of pharmacological interventions on anthropometric parameters in women with PCOS.

396 However, there are some limitations that must be considered for this systematic review. We applied 397 a language filter and only RCTs reported in English language were included; hence several trials in 398 foreign languages may not have been retrieved. Assessing such trials requires sophisticated 399 translation, which is challenging and might also affect the methodology of this review. Furthermore, 400 only fully published trials were eligible to be included in the review. The majority of the trials were of 401 small sample size and the statistical power used to calculate sample size and to detect the significant 402 differences between the groups was not fully reported. All the trials were of short duration and 403 reported baseline and immediate post-intervention data. Therefore, the long-term effects of different 404 pharmacological interventions in women with PCOS is not clear.

405 Conclusion

406 Metformin, alone or in combination with other medications and irrespective of the dosage and 407 duration of therapy can significantly reduce mean body weight, BMI and WC in women with PCOS. 408 Orlistat also significantly reduced mean BMI compared with placebo. On the other hand, both 409 rosiglitazone and pioglitazone, alone or in combination with other medications were associated with 410 significant increases in mean body weight, BMI and WC.

411 Acknowledgement

We thank Dr. Gamila Hassan at the National Medical Library (UAEU) for her support with locating and
uploading full-text papers to Covidence for screening and for assessing for predatory journals.

414

416 Data availability

- 417 The datasets generated and analysed for this review are available upon reasonable request to the
- 418 authors.

419 Funding

- 420 This systematic review was completed as part of a self-funded PhD project for M.A and no external
- 421 fund was received.

422 Conflict of interest

- 423 None to declare.
- 424 Ethical approval
- 425 Not needed as no patients were involved.

426 Authors contributions

427 M.A; designed the review, assessed the quality, extracted, collected, and analysed the data, written, 428 revised, and edited the final manuscript. N.S; assessed the quality, extracted, and collected the data, 429 and revised and edited the final manuscript. H.D; revised and edited the final manuscript. L. Ö; developed and conducted the database searches and revised and edited the final manuscript. R.H.A; 430 contributed to the meta-analysis and participated in the critical discussion and revised and edited the 431 432 final manuscript. S.A; participated in the critical discussion and revised the final draft of the 433 manuscript. T.S; acted as mediator for the assessment of the quality of the evidence, supervised the 434 study, participated in the critical discussion, revised, and edited the final manuscript.

435

437 References

- 4381.Strowitzki T. Advanced diagnosis of polycystic ovary syndrome-new prediction models with439standard parameters. *Fertil Steril.* 2021;115(1):92-93.
- 4402.Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with441psychological, reproductive and metabolic manifestations that impacts on health across the442lifespan. BMC Med. 2010;8:41.
- 4433.Hoeger KM, Dokras A, Piltonen T. Update on PCOS: Consequences, Challenges and Guiding444Treatment. J Clin Endocrinol Metab. 2020.
- 445 4. Abdalla MA, Deshmukh H, Atkin S, Sathyapalan T. A review of therapeutic options for 446 managing the metabolic aspects of polycystic ovary syndrome. *Ther Adv Endocrinol Metab.* 447 2020;11:2042018820938305.
- 4485.Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: etiology,449pathogenesis and diagnosis. Nat Rev Endocrinol. 2011;7(4):219-231.
- 450 6. Mu N, Zhu Y, Wang Y, Zhang H, Xue F. Insulin resistance: a significant risk factor of endometrial
 451 cancer. *Gynecol Oncol.* 2012;125(3):751-757.
- 452 7. Shao Y, Cheng S, Hou J, et al. Insulin is an important risk factor of endometrial cancer among
 453 premenopausal women: a case-control study in China. *Tumour Biol.* 2016;37(4):4721-4726.
- 4548.Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R. Obesity and the polycystic ovary455syndrome. Int J Obes Relat Metab Disord. 2002;26(7):883-896.
- 456 9. Motta AB. The role of obesity in the development of polycystic ovary syndrome. *Curr Pharm* 457 *Des.* 2012;18(17):2482-2491.
- Teede HJ, Misso ML, Costello MF, et al. Recommendations from the international evidence based guideline for the assessment and management of polycystic ovary syndrome. *Hum Reprod.* 2018;33(9):1602-1618.
- 461 11. Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor.
 462 *Diabetes.* 1998;47(4):507-514.
- 46312.Xu Y, Wu Y, Huang Q. Comparison of the effect between pioglitazone and metformin in
treating patients with PCOS:a meta-analysis. Arch Gynecol Obstet. 2017;296(4):661-677.
- 465 13. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline
 466 for reporting systematic reviews. *BMJ*. 2021;372:n71.
- 467 14. Babineau J. Product review: covidence (systematic review software). Journal of the Canadian
 468 Health Libraries Association/Journal de l'Association des bibliothèques de la santé du Canada.
 469 2014;35(2):68-71.
- 470 15. Hupe M. EndNote X9. Journal of Electronic Resources in Medical Libraries. 2019;16(3-4):117471 119.
- 472 16. Das S, Chatterjee SS. Cabell's blacklist: A new way to tackle predatory journals. *Indian journal*473 of psychological medicine. 2018;40(2):197-198.
- 474 17. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk
 475 of bias in randomised trials. *BMJ.* 2011;343:d5928.
- 476 18. Higgins JP, Thomas J, Chandler J, et al. *Cochrane handbook for systematic reviews of*477 *interventions.* John Wiley & Sons; 2019.
- 47819.Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of479evidence and strength of recommendations. *BMJ.* 2008;336(7650):924-926.
- 480 20. Amiri M, Golsorkhtabaramiri M, Esmaeilzadeh S, et al. Effect of Metformin and Flutamide on
 481 Anthropometric Indices and Laboratory Tests in Obese/Overweight PCOS Women under
 482 Hypocaloric Diet. *Journal of reproduction & infertility.* 2014;15(4):205-213.
- Brettenthaler N, De Geyter C, Huber PR, Keller U. Effect of the insulin sensitizer pioglitazone
 on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic
 ovary syndrome. *The Journal of clinical endocrinology and metabolism*. 2004;89(8):3835-3840.

- 486 22. Cetinkalp S, Karadeniz M, Erdogan M, Ozgen G, Saygl F, Ylmaz C. The effects of rosiglitazone,
 487 metformin, and estradiol-cyproterone acetate on lean patients with polycystic ovary
 488 syndrome. *Endocrinologist.* 2009;19(3):94-97.
- 23. Cho LW, Kilpatrick ES, Keevil BG, Coady AM, Atkin SL. Effect of metformin, orlistat and
 pioglitazone treatment on mean insulin resistance and its biological variability in polycystic
 ovary syndrome. *Clinical endocrinology*. 2009;70(2):233-237.
- 492 24. Devin JK, Nian H, Celedonio JE, Wright P, Brown NJ. Sitagliptin Decreases Visceral Fat and
 493 Blood Glucose in Women With Polycystic Ovarian Syndrome. *J Clin Endocrinol Metab.*494 2020;105(1).
- Diamanti-Kandarakis E, Katsikis I, Piperi C, Alexandraki K, Panidis D. Effect of long-term orlistat
 treatment on serum levels of advanced glycation end-products in women with polycystic
 ovary syndrome. *Clinical Endocrinology*. 2007;66(1):103-109.
- 498 26. Eisenhardt S, Schwarzmann N, Henschel V, et al. Early effects of metformin in women with
 499 polycystic ovary syndrome: a prospective randomized, double-blind, placebo-controlled trial.
 500 The Journal of clinical endocrinology and metabolism. 2006;91(3):946-952.
- 501 27. Elkind-Hirsch K, Marrioneaux O, Bhushan M, Vernor D, Bhushan R. Comparison of single and
 502 combined treatment with exenatide and metformin on menstrual cyclicity in overweight
 503 women with polycystic ovary syndrome. *The Journal of clinical endocrinology and metabolism.*504 2008;93(7):2670-2678.
- 505 28. Ferjan S, Janez A, Jensterle M. Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Prevented Weight
 506 Regain in Obese Women with Polycystic Ovary Syndrome Previously Treated with Liraglutide:
 507 A Pilot Randomized Study. *Metabolic syndrome and related disorders*. 2017;15(10):515-520.
- 508 29. Ferjan S, Janez A, Jensterle M. DPP4 INHIBITOR SITAGLIPTIN AS A POTENTIAL TREATMENT
 509 OPTION IN METFORMIN-INTOLERANT OBESE WOMEN WITH POLYCYSTIC OVARY SYNDROME:
 510 A PILOT RANDOMIZED STUDY. Endocrine practice : official journal of the American College of
 511 Endocrinology and the American Association of Clinical Endocrinologists. 2018;24(1):69-77.
- 512 30. Ghandi S, Aflatoonian A, Tabibnejad N, Moghaddam MH. The effects of metformin or orlistat
 513 on obese women with polycystic ovary syndrome: a prospective randomized open-label study.
 514 Journal of assisted reproduction and genetics. 2011;28(7):591-596.
- 515 31. Heidari B, Lerman A, Lalia AZ, Lerman LO, Chang AY. Effect of Metformin on Microvascular
 516 Endothelial Function in Polycystic Ovary Syndrome. *Mayo Clinic proceedings*.
 517 2019;94(12):2455-2466.
- Javanmanesh F, Kashanian M, Rahimi M, Sheikhansari N. A comparison between the effects
 of metformin and N-acetyl cysteine (NAC) on some metabolic and endocrine characteristics
 of women with polycystic ovary syndrome. *Gynecological endocrinology : the official journal*of the International Society of Gynecological Endocrinology. 2016;32(4):285-289.
- Jensterle M, Janez A, Mlinar B, Marc J, Prezelj J, Pfeifer M. Impact of metformin and
 rosiglitazone treatment on glucose transporter 4 mRNA expression in women with polycystic
 ovary syndrome. *European journal of endocrinology*. 2008;158(6):793-801.
- Jensterle M, Kravos N, Janež A. Short-term effectiveness of low dose liraglutide in combination
 with metformin vs. high dose liraglutide alone in treatment of obesity. *Diabetes.*2016;65((Jensterle M.; Kravos N.; Janež A.) Ljubljana, Slovenia):A70.
- 35. Jensterle M, Kravos NA, Goričar K, Janez A. Short-term effectiveness of low dose liraglutide in
 combination with metformin versus high dose liraglutide alone in treatment of obese PCOS:
 randomized trial. *BMC endocrine disorders.* 2017;17(1):5.
- 53136.Karimzadeh MA, Eftekhar M, Taheripanah R, Tayebi N, Sakhavat L, Zare F. The effect of532administration of metformin on lipid profile changes and insulin resistance in patients with533polycystic ovary syndrome. *Middle East Fertil Soc J.* 2007;12(3):174-178.
- 53437.Kazerooni T, Shojaei-Baghini A, Dehbashi S, Asadi N, Ghaffarpasand F, Kazerooni Y. Effects of535metformin plus simvastatin on polycystic ovary syndrome: a prospective, randomized, double-536blind, placebo-controlled study. Fertility and sterility. 2010;94(6):2208-2213.

- 53738.Kilicdag EB, Bagis T, Zeyneloglu HB, et al. Homocysteine levels in women with polycystic ovary538syndrome treated with metformin versus rosiglitazone: a randomized study. Human539reproduction (Oxford, England). 2005;20(4):894-899.
- 54039.Kocak M, Caliskan E, Simsir C, Haberal A. Metformin therapy improves ovulatory rates, cervical541scores, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary542syndrome. Fertility and sterility. 2002;77(1):101-106.
- 54340.Lam PM, Tam WH, Ma RC, et al. The reproductive and metabolic effect of rosiglitazone on544Chinese women with polycystic ovarian syndrome--a double-blind randomized placebo-545controlled study. *Fertility and sterility*. 2011;96(2):445-451.e441.
- Li Y, Tan J, Wang Q, Duan C, Hu Y, Huang W. Comparing the individual effects of metformin and rosiglitazone and their combination in obese women with polycystic ovary syndrome: a randomized controlled trial. *Fertility and sterility*. 2020;113(1):197-204.
- Lingaiah S, Morin-Papunen L, Risteli J, Tapanainen JS. Metformin decreases bone turnover
 markers in polycystic ovary syndrome: a post hoc study. *Fertility and sterility*.
 2019;112(2):362-370.
- Liu X, Zhang Y, Zheng SY, et al. Efficacy of exenatide on weight loss, metabolic parameters and
 pregnancy in overweight/obese polycystic ovary syndrome. *Clinical endocrinology*.
 2017;87(6):767-774.
- Mohiyiddeen L, Watson AJ, Apostolopoulos NV, Berry R, Alexandraki KI, Jude EB. Effects of
 low-dose metformin and rosiglitazone on biochemical, clinical, metabolic and biophysical
 outcomes in polycystic ovary syndrome. *Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology.* 2013;33(2):165-170.
- Moini A, Kanani M, Kashani L, Hosseini R, Hosseini L. Effect of orlistat on weight loss, hormonal
 and metabolic profiles in women with polycystic ovarian syndrome: a randomized doubleblind placebo-controlled trial. *Endocrine*. 2015;49(1):286-289.
- Morin-Papunen L, Rantala AS, Unkila-Kallio L, et al. Metformin improves pregnancy and livebirth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double-blind,
 placebo-controlled randomized trial. *The Journal of clinical endocrinology and metabolism*.
 2012;97(5):1492-1500.
- Morteza Taghavi S, Rokni H, Fatemi S. Metformin decreases thyrotropin in overweight women
 with polycystic ovarian syndrome and hypothyroidism. *Diabetes & vascular disease research*.
 2011;8(1):47-48.
- Muneyyirci-Delale O, Kaplan J, Joulak I, Yang L, Von Gizycki H, Nacharaju VL. Serum free fatty
 acid levels in PCOS patients treated with glucophage, magnesium oxide and spironolactone. *Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.* 2013;29(5):474-477.
- 49. Nemati M, Nemati S, Taheri AM, Heidari B. Comparison of metformin and N-acetyl cysteine,
 as an adjuvant to clomiphene citrate, in clomiphene-resistant women with polycystic ovary
 syndrome. Journal of Gynecology Obstetrics and Human Reproduction. 2017;46(7):579-585.
- 576 50. Romualdi D, Giuliani M, Cristello F, et al. Metformin effects on ovarian ultrasound appearance
 577 and steroidogenic function in normal-weight normoinsulinemic women with polycystic ovary
 578 syndrome: a randomized double-blind placebo-controlled clinical trial. *Fertility and sterility*.
 579 2010;93(7):2303-2310.
- 580 51. Rezai M, Jamshidi M, Mohammadbeigi R, Seyedoshohadaei F, Mohammadipour S, Moradi G.
 581 Comparing the Effect of Metformin and Acarbose Accompanying Clomiphene on the
 582 Successful Ovulation Induction in Infertile Women with Polycystic Ovary Syndrome. *Global*583 *journal of health science.* 2016;8(9):54516.
- 584 52. Sathyapalan T, Kilpatrick ES, Coady AM, Atkin SL. The effect of atorvastatin in patients with
 polycystic ovary syndrome: a randomized double-blind placebo-controlled study. *The Journal* 586 of clinical endocrinology and metabolism. 2009;94(1):103-108.

- 587 53. Shahebrahimi K, Jalilian N, Bazgir N, Rezaei M. Comparison clinical and metabolic effects of
 588 metformin and pioglitazone in polycystic ovary syndrome. *Indian J Endocrinol Metab.*589 2016;20(6):805-809.
- 59054.Sova H, Puistola U, Morin-Papunen L, Karihtala P. Metformin decreases serum 8-hydroxy-2'-591deoxyguanosine levels in polycystic ovary syndrome. Fertility and sterility. 2013;99(2):593-592598.
- 593 55. Tao T, Wu P, Wang Y, Liu W. Comparison of glycemic control and β-cell function in new onset
 594 T2DM patients with PCOS of metformin and saxagliptin monotherapy or combination
 595 treatment. *BMC Endocrine Disorders.* 2018;18(1):14.
- 596 56. Underdal MO, Stridsklev S, Oppen IH, Høgetveit K, Andersen MS, Vanky E. Does Metformin
 597 Treatment During Pregnancy Modify the Future Metabolic Profile in Women With PCOS? *The* 598 Journal of clinical endocrinology and metabolism. 2018;103(6):2408-2413.
- 57. Vanky E, Salvesen KA, Heimstad R, Fougner KJ, Romundstad P, Carlsen SM. Metformin reduces
 pregnancy complications without affecting androgen levels in pregnant polycystic ovary
 syndrome women: results of a randomized study. *Human reproduction (Oxford, England).*2004;19(8):1734-1740.
- 58. Yilmaz M, Karakoç A, Törüner FB, et al. The effects of rosiglitazone and metformin on
 menstrual cyclicity and hirsutism in polycystic ovary syndrome. *Gynecological endocrinology :*the official journal of the International Society of Gynecological Endocrinology.
 2005;21(3):154-160.
- 60759.Zahra M, Shah M, Ali A, Rahim R. Effects of Metformin on Endocrine and Metabolic Parameters608in Patients with Polycystic Ovary Syndrome. Hormone and metabolic research = Hormon- und609Stoffwechselforschung = Hormones et metabolisme. 2017;49(2):103-108.
- 60. Zheng S, Zhang Y, Long T, et al. Short term monotherapy with exenatide is superior to
 metformin in weight loss, improving insulin resistance and inflammation in Chinese
 overweight/obese PCOS women. *Obesity Medicine*. 2017;7((Wang F.) Department of
 Obstetrics and Gynecology, The Third Affiliated Hospital of Guangzhou Medical University,
 Guangzhou, Guangdong, China):15-20.
- 61. Ziaee A, Oveisi S, Abedini A, Hashemipour S, Karimzadeh T, Ghorbani A. Effect of metformin
 616 and pioglitazone treatment on cardiovascular risk profile in polycystic ovary syndrome. *Acta*617 *medica Indonesiana*. 2012;44(1):16-22.
- 618 62. Rotterdam EA-SPCWG. Revised 2003 consensus on diagnostic criteria and long-term health 619 risks related to polycystic ovary syndrome. *Fertil Steril.* 2004;81(1):19-25.
- 620 63. Aroda VR, Ciaraldi TP, Burke P, et al. Metabolic and hormonal changes induced by pioglitazone
 621 in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial. *The Journal of*622 *clinical endocrinology and metabolism.* 2009;94(2):469-476.
- 623 64. Ashraf Ganie M, Khurana ML, Eunice M, Gulati M, Dwivedi SN, Ammini AC. Erratum:
 624 Comparison of efficacy of spironolactone with metformin in the management of polycystic
 625 ovary syndrome: An open-labeled study (The Journal of Clinical Endocrinology & Metabolism
 626 (2004) 89 (2756-2762)). J Clin Endocrinol Metab. 2004;89(9):4655.
- 627 65. Elkind-Hirsch KE, Paterson MS, Seidemann EL, Gutowski HC. Short-term therapy with
 628 combination dipeptidyl peptidase-4 inhibitor saxagliptin/metformin extended release (XR) is
 629 superior to saxagliptin or metformin XR monotherapy in prediabetic women with polycystic
 630 ovary syndrome: a single-blind, randomized, pilot. *Fertility and sterility*. 2017;107(1):253631 260.e251.
- 632 66. Ganie MA, Khurana ML, Nisar S, et al. Improved efficacy of low-dose spironolactone and
 633 metformin combination than either drug alone in the management of women with polycystic
 634 ovary syndrome (PCOS): a six-month, open-label randomized study. *The Journal of clinical*635 *endocrinology and metabolism.* 2013;98(9):3599-3607.
- 636 67. Hanjalic-Beck A, Gabriel B, Schaefer W, et al. Metformin versus acarbose therapy in patients 637 with polycystic ovary syndrome (PCOS): a prospective randomised double-blind study.

638 *Gynecological endocrinology : the official journal of the International Society of Gynecological* 639 *Endocrinology.* 2010;26(9):690-697.

- 640 68. Mehrabian F, Ghasemi-Tehrani H, Mohamadkhani M, Moeinoddini M, Karimzadeh P.
 641 Comparison of the effects of metformin, flutamide plus oral contraceptives, and simvastatin
 642 on the metabolic consequences of polycystic ovary syndrome. *J Res Med Sci.* 2016;21:7.
- 643 69. Jensterle M, Salamun V, Kocjan T, Bokal EV, Janez A. Short term monotherapy with GLP-1
 644 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight
 645 loss in obese PCOS women: A pilot randomized study. *Endocrine Reviews*. 2015;36((Janez A.)
 646 University Medical Center Ljubljana, Ljubljana, Slovenia).
- For and rosiglitazone treatment in women with polycystic ovary syndrome. *European journal of endocrinology*. 2008;159(4):399-406.
- Jensterle Sever M, Kocjan T, Pfeifer M, Kravos NA, Janez A. Short-term combined treatment
 with liraglutide and metformin leads to significant weight loss in obese women with polycystic
 ovary syndrome and previous poor response to metformin. *European journal of endocrinology*. 2014;170(3):451-459.
- Sönmez AS, Yasar L, Savan K, et al. Comparison of the effects of acarbose and metformin use
 on ovulation rates in clomiphene citrate-resistant polycystic ovary syndrome. *Human reproduction (Oxford, England)*. 2005;20(1):175-179.
- 657 73. Batista JG, Soares JM, Maganhin CC, Simões RS, Tomaz G, Baracat EC. Assessing the benefits
 658 of rosiglitazone in women with polycystic ovary syndrome through its effects on insulin-like
 659 growth factor 1, insulin-like growth factor-binding protein-3 and insulin resistance: a pilot
 660 study. *Clinics (Sao Paulo, Brazil).* 2012;67(3):283-287.
- Azziz R, Carmina E, Dewailly D, et al. Positions statement: criteria for defining polycystic ovary
 syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society
 guideline. J Clin Endocrinol Metab. 2006;91(11):4237-4245.
- 664 75. Chen Z, Zhang M, Qiao Y, Yang J. Effects of letrozole in combination with low-dose
 665 intramuscular injection of human menopausal gonadotropin on ovulation and pregnancy of
 666 156 patients with polycystic ovary syndrome. *Pakistan Journal of Medical Sciences*.
 667 2016;32(6):1434-1438.
- 668 76. Chou KH, von Eye Corleta H, Capp E, Spritzer PM. Clinical, metabolic and endocrine parameters
 669 in response to metformin in obese women with polycystic ovary syndrome: a randomized,
 670 double-blind and placebo-controlled trial. *Hormone and metabolic research = Hormon- und*671 *Stoffwechselforschung = Hormones et metabolisme.* 2003;35(2):86-91.
- 672 77. Gambineri A, Pelusi C, Genghini S, et al. Effect of flutamide and metformin administered alone
 673 or in combination in dieting obese women with polycystic ovary syndrome. *Clinical*674 *endocrinology*. 2004;60(2):241-249.
- Kord J, Thomas R, Fox B, Acharya U, Wilkin T. The effect of metformin on fat distribution and
 the metabolic syndrome in women with polycystic ovary syndrome--a randomised, doubleblind, placebo-controlled trial. *BJOG : an international journal of obstetrics and gynaecology.*2006;113(7):817-824.
- Ng EH, Wat NM, Ho PC. Effects of metformin on ovulation rate, hormonal and metabolic
 profiles in women with clomiphene-resistant polycystic ovaries: a randomized, doubleblinded placebo-controlled trial. *Human reproduction (Oxford, England)*. 2001;16(8):16251631.
- 68380.Palomba S, Falbo A, Russo T, et al. Insulin sensitivity after metformin suspension in normal-684weight women with polycystic ovary syndrome. The Journal of clinical endocrinology and685metabolism. 2007;92(8):3128-3135.
- 81. Vandermolen DT, Ratts VS, Evans WS, Stovall DW, Kauma SW, Nestler JE. Metformin increases
 the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic

688ovary syndrome who are resistant to clomiphene citrate alone. Fertility and sterility.6892001;75(2):310-315.


- 82. Yarali H, Yildiz BO, Demirol A, et al. Co-administration of metformin during rFSH treatment in
 patients with clomiphene citrate-resistant polycystic ovarian syndrome: a prospective
 randomized trial. *Human reproduction (Oxford, England).* 2002;17(2):289-294.
- 693 83. Cheng F, Zhao L, Wu Y, et al. Serum vascular endothelial growth factor B is elevated in women
 694 with polycystic ovary syndrome and can be decreased with metformin treatment. *Clin*695 *Endocrinol (Oxf)*. 2016;84(3):386-393.
- 69684.Naka KK, Kalantaridou SN, Kravariti M, et al. Effect of the insulin sensitizers metformin and697pioglitazone on endothelial function in young women with polycystic ovary syndrome: a698prospective randomized study. Fertility and sterility. 2011;95(1):203-209.
- 699 85. Ortega-González C, Luna S, Hernández L, et al. Responses of serum androgen and insulin
 700 resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic
 701 ovary syndrome. *The Journal of clinical endocrinology and metabolism.* 2005;90(3):1360-1365.
- Sohrevardi SM, Nosouhi F, Hossein Khalilzade S, et al. Evaluating the effect of insulin
 sensitizers metformin and pioglitazone alone and in combination on women with polycystic
 ovary syndrome: An RCT. *International journal of reproductive biomedicine (Yazd, Iran).*2016;14(12):743-754.
- 87. Jensterle M, Kravos NA, Pfeifer M, Kocjan T, Janez A. A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome. *Hormones (Athens).*2015;14(1):81-90.
- 88. Glintborg D, Hermann AP, Andersen M, et al. Effect of pioglitazone on glucose metabolism
 and luteinizing hormone secretion in women with polycystic ovary syndrome. *Fertility and*sterility. 2006;86(2):385-397.
- 89. Glintborg D, Højlund K, Andersen M, Henriksen JE, Beck-Nielsen H, Handberg A. Soluble CD36
 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary
 syndrome and significantly reduced during pioglitazone treatment. *Diabetes care*.
 2008;31(2):328-334.
- 90. Glintborg D, Støving RK, Hagen C, et al. Pioglitazone treatment increases spontaneous growth
 hormone (GH) secretion and stimulated GH levels in polycystic ovary syndrome. *The Journal*of clinical endocrinology and metabolism. 2005;90(10):5605-5612.
- P1. Legro RS, Zaino RJ, Demers LM, et al. The effects of metformin and rosiglitazone, alone and in
 combination, on the ovary and endometrium in polycystic ovary syndrome. *American journal* of obstetrics and gynecology. 2007;196(4):402.e401-410; discussion 402.e410.
- Steiner CA, Janez A, Jensterle M, Reisinger K, Forst T, Pfützner A. Impact of treatment with
 rosiglitazone or metformin on biomarkers for insulin resistance and metabolic syndrome in
 patients with polycystic ovary syndrome. *Journal of diabetes science and technology.*2007;1(2):211-217.
- 93. Ahmad J, Shukla N, Khan AR, Ahmed F, Siddiqui MA. Comparison of metabolic effects of
 metformin and rosiglitazone in the management of polycystic ovary syndrome (PCOS): A
 prospective, parallel, randomized, open-label study. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews.* 2008;2(1):37-46.
- 73194.Jayagopal V, Kilpatrick ES, Holding S, Jennings PE, Atkin SL. Orlistat is as beneficial as732metformin in the treatment of polycystic ovarian syndrome. The Journal of clinical733endocrinology and metabolism. 2005;90(2):729-733.
- Paredes Palma JC, López Byhen E, Ibáñez L, Balladares Macedo L, Paredes Palma C, Ramírez
 Velázquez C. Comparative treatment between sitagliptin vs. metformin, alone or in
 combination, in patients with polycystic ovary syndrome. A clinical entity at high risk for
 developing diabetes mellitus and gestational diabetes: A pilot study. *Revista Medica del Hospital General de Mexico.* 2018;81(1):15-26.

- 739 96. Ciotta L, Calogero AE, Farina M, De Leo V, La Marca A, Cianci A. Clinical, endocrine and
 740 metabolic effects of acarbose, an alpha-glucosidase inhibitor, in PCOS patients with increased
 741 insulin response and normal glucose tolerance. *Human reproduction (Oxford, England)*.
 742 2001;16(10):2066-2072.
- Penna IA, Canella PR, Reis RM, Silva de Sá MF, Ferriani RA. Acarbose in obese patients with
 polycystic ovarian syndrome: a double-blind, randomized, placebo-controlled study. *Human reproduction (Oxford, England).* 2005;20(9):2396-2401.
- Navali N, Pourabolghasem S, Fouladi RF, Nikpour MA. Therapeutic effects of biguanide vs.
 statin in polycystic ovary syndrome: a randomized clinical trial. *Pakistan journal of biological sciences : PJBS.* 2011;14(11):658-663.
- Puurunen J, Piltonen T, Puukka K, et al. Statin therapy worsens insulin sensitivity in women
 with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebocontrolled study. *The Journal of clinical endocrinology and metabolism*. 2013;98(12):47984807.
- Cataldo NA, Abbasi F, McLaughlin TL, et al. Metabolic and ovarian effects of rosiglitazone
 treatment for 12 weeks in insulin-resistant women with polycystic ovary syndrome. *Hum Reprod.* 2006;21(1):109-120.
- 756101.Dereli D, Dereli T, Bayraktar F, Ozgen AG, Yilmaz C. Endocrine and metabolic effects of757rosiglitazone in non-obese women with polycystic ovary disease. *Endocr J.* 2005;52(3):299-758308.
- Rautio K, Tapanainen JS, Ruokonen A, Morin-Papunen LC. Endocrine and metabolic effects of
 rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study. *Hum Reprod.* 2006;21(6):1400-1407.
- Trolle B, Lauszus FF, Frystyk J, Flyvbjerg A. Adiponectin levels in women with polycystic ovary
 syndrome: impact of metformin treatment in a randomized controlled study. *Fertility and sterility*. 2010;94(6):2234-2238.
- Naderpoor N, Shorakae S, de Courten B, Misso ML, Moran LJ, Teede HJ. Metformin and
 lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis. *Hum Reprod Update*. 2015;21(5):560-574.
- Guan Y, Wang D, Bu H, Zhao T, Wang H. The Effect of Metformin on Polycystic Ovary Syndrome
 in Overweight Women: A Systematic Review and Meta-Analysis of Randomized Controlled
 Trials. Int J Endocrinol. 2020;2020:5150684.
- Du Q, Wang YJ, Yang S, Wu B, Han P, Zhao YY. A systematic review and meta-analysis of
 randomized controlled trials comparing pioglitazone versus metformin in the treatment of
 polycystic ovary syndrome. *Curr Med Res Opin.* 2012;28(5):723-730.
- Panda SR, Jain M, Jain S, Saxena R, Hota S. Effect of Orlistat Versus Metformin in Various
 Aspects of Polycystic Ovarian Syndrome: A Systematic Review of Randomized Control Trials. J
 Obstet Gynaecol India. 2018;68(5):336-343.
- Graff SK, Mario FM, Ziegelmann P, Spritzer PM. Effects of orlistat vs. metformin on weight
 loss-related clinical variables in women with PCOS: systematic review and meta-analysis. *Int J Clin Pract.* 2016;70(6):450-461.
- Aghili R, Malek M, Valojerdi AE, Banazadeh Z, Najafi L, Khamseh ME. Body composition in adults with newly diagnosed type 2 diabetes: effects of metformin. *J Diabetes Metab Disord*.
 2014;13(1):88.
- Maruthur NM, Tseng E, Hutfless S, et al. Diabetes Medications as Monotherapy or Metformin Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis. Ann
 Intern Med. 2016;164(11):740-751.
- Filipova E, Uzunova K, Kalinov K, Vekov T. Effects of pioglitazone therapy on blood parameters,
 weight and BMI: a meta-analysis. *Diabetol Metab Syndr.* 2017;9:90.

Song LL, Wang X, Yang ZJ, et al. Factors associated with improvement in waist-to-height ratio
 among newly diagnosed type 2 diabetes patients treated with acarbose or metformin: A
 randomized clinical trial study. *World J Diabetes*. 2020;11(11):514-526.

791			
792			
793			
794			
795			
796			
797			
798			
799			
800			
801			
802			
803			
804			
805			
806			
807			
808			
809			
810			
811			

	 Inclusion criteria Study design: randomised controlled trials including (randomised open-label trials, double-blind controlled trials, crossover randomised trials, parallel randomised trials). Population: adult females aged 18 and over with a diagnosis of PCOS based on a robust diagnostic criterion. Comparator: reported pharmacological interventions compared to placebo or other pharmacological agents. Outcomes: reported outcomes such as BMI, body weight, waist circumference and waist to hip ratio. Exclusion criteria Study design: case studies, cross-sectional studies and animal studies. Patients population: adolescents females, postmenopausal women, and women without PCOS. Comparators: non-pharmacological interventions, pharmacological interventions versus dietary interventions, pharmacological interventions versus physical activities or surgery.
817 818	
819	
820	
821	
822	
823	
824	
825	
826	
827	
828	
829	
830	
831	
832	
833	
834	
835	



Author Study	y design	Country	PCOS diagnostic Criteria	Participants characteristics (PCOS)	Interventions	Durations	Outcomes
Amiri et al ²⁰	RCT	Iran	Rotterdam	Age:25.6±4.02 BMI: 28.9±5	Metf, Flu, Metf+ Flu, Placebo	6 months	BMI, WHR, WC, FBG,LDL,HDL, TG FAI.
.Ahmad et al ⁹³	RCT	India	NIH	Age: 22.81± 4.52 BMI: 27.66 ±5.44	Rosig, Metf	12 months	WHR, BMI
Aroda et al ⁶³	RCT	USA	NIH	Age: 27.87 ±0.87 BMI: 36.29 ±1.34	Piog, Placebo	6 months	Weight, BMI, WHR, WC, FBG,FI
Ashraf Ganie et al ⁶⁴	RCT	India	NIH	Age: 22.9 ±5.3 BMI: 26.8±4.0	Spironolactone vs Met	3 months	BMI,FBG,FI, WHR
atista et al ⁷³	RCT	Brazil	AES-2006	Age: 24.5±4.33 BMI: 27.89±6.10	Rosig, placebo	12 weeks	FBG.FI,HOMA-IR
Brettenthaler et al ²¹	RCT	Switzerland	Rotterdam	Age: 30.2± 1.4 BMI: 29.4± 1.7	Piog, placebo	3 months	BMI,WHR,FBG, FI, HOMA-IR
Cataldo et al ¹⁰⁰	RCT	USA	NICHD	Age: 29.3 ± 1.5 BMI: 37.2 ± 2.1	Rosig 2mg, 4mg, 8 mg	12 weeks	BMI, WHR, Wt
Cheng et al ⁷⁵	RCT	Australia	Rotterdam	Age: 26 ± 4 BMI:24.2±5.3	Metf, placebo	6 months	Wt, BMI, WC, WHR, LDL,HDL, TG,TC,HOMA-IR, HOMA-B
Chou et al ⁷⁶	RCT	Brazil	N/A	Age:24±5 BMI:35.6±4.9	Metf, placebo	3 months	BMI,WHR,FBG, FI, TG,TC,HDL, LDI
Cetinkalp et al ²²	RCT	Turkey	Rotterdam	Age: N/A BMA:25.82±6.12	Met, Rosigl , ECA	4 months	FBG,FI, Wt, BMI, HOMA-IR, TC, TG,HDL,LDL
Cho et al ²³	RCT	UK	Rotterdam	Age: 26·4 ± 1·5 BMI: 36·0 ± 1·2	Metf, Orlistat, Piog	12 weeks	BMI, HOMA-IR
Ciotta et al ⁹⁶	RCT	Italy	N/A	Age:20.5±0.6 BMI:22.7±0.34	Acarbose, Placebo	3 months	BMI, PRL
Dereli et al ¹⁰¹	RCT	Turkey	NICHD	Age: 31.4 ± 0.9 BMI: 24.2 ± 1.3	Rosig 2mg, 4 mg	8 months	BMI, WHR
Diamanti-Kandarakis et al ²	⁵ RCT	Greece	Rotterdam	Age: 27·52 ± 5·77 BMI: 35·43 ± 5·3	Orli, placebo	6 months	BMI,WHR, HOMA
Devin et al ²⁴	RCT-cross over	USA	Rotterdam	Age:N/A BMI:N/A	Sitag, placebo	4 weeks	BMI,WHR,WC, LDL.HDL, TC
lkind-Hirsch et al ²⁷	RCT	USA	Rotterdam	Age: 28.2 ± 1.1 BMI: 39.9 ±1.5	Exen, Metf,Exen+Metf	24 weeks	Wt, BMI, CRP, TG, TC,HDL,LDL
lkind-Hirsch et al ⁶⁵	RCT	USA	NIH	Age: 29.9± 7 BMA: 42.1 ±7.3	Sax, Metf, Sax+Metf	16 weeks	FBG,FI, HDL,TG, LDL,HOMA-IR
isenhardt et al ²⁶	RCT	Germany	Rotterdam	Age: 27.0 BMI: 28.9	Metf, Placebo	12 weeks	FBG.FI,HOMA-IR
erjan et al ²⁸	RCT	Slovenia	Rotterdam	Age: 34.3 ± 6.8 BMI: 36.3 ±5.2	Metf, Metf+Sitag	12 weeks	Wt,BMI,WC TC,TG,LDL, HDL, HOMA-IR
erjan et al ²⁹	RCT	Slovenia	Rotterdam	Age: 35.0 ± 7.2 BMI: 36.9 ± 5.5	Sitag, Placebo	12 weeks	HOMA-IR, BMI, HOMA-B, FBG

Table 2: Characteristics of the included RCTs

Table2 continued							
Glintborg et al ⁹⁰	RCT	USA	N/A	Age: 32 BMI: N/A	Piog, Placebo	16 weeks	FI, HOMA-IR
Glintborg et al ⁸⁸	RCT	USA	N/A	Age: 32 BMI: 32.2	Piog,Plcebo	16 weeks	BMI,WHR, WC, FI
Glintborg et al ⁸⁹	RCT	Denmark	N/A	Age: N/A BMI: 33·1	Piog, placebo	16 weeks	BMI, CRP, LDL
Gambineri et al ⁷⁷	RCT	Italy	N/A	Age: 27·1 ± 3·6 BMI: 37·6 ± 4·1	Plac, metfo, flut, metf + flut	6 months	FBG,FI, Wt, BMI, HOMA-IR
Ghandi et al ³⁰	RCT	Iran	Rotterdam	Age: 27±4.92 BMI: 34.88±4.90	Orlistat, Metf	3 months	BMI,WC, TC, TG
Ganie et al ⁶⁶	RCT	USA	NIH	Age: 22.6 ±5.0 BMI: 26.5 ±5.6	Spironolactone, Metf	6 months	WHR,BMI,FBG,FI
Hanjalic-Beck et al ⁶⁷	RCT	Germany	NIH	Age:N/A BMI:N/A	Metf, Acarbose	12 weeks	BMI,FBG,FI
Heidari et al ³¹	RCT	USA	Rotterdam	Age: 32.47.5 BMI: 37.19.1	Metf, placebo	3 months	BMI,WC,WHR, Weight
ayagopal et al ⁹⁴	RCT	UK	N/A	Age: 27 ±0.9 BMI: 36.7 ±3.3	Orlistat, Metf	3 months	FBG, FI, TC,TG, HDL
avanmanesh et al ³²	RCT	Iran	Rotterdam	Age: 29.75 ± 4.90 BMI: 29.05 ± 2.80	Metf, NAC	24 weeks	BMI, FBG,FI, LDL, TC,TG, HDL ,HOMA-IR
lensterle et al ⁸⁷	RCT	Slovenia	NIH	Age: 27.6±7.2 BMI: 39.5±6.2	Metf, Lira	12 weeks	BMI,WC, TC,TG,LDL,HDL
lensterle et al ⁶⁹	RCT	Slovenia	Rotterdam	Age: 30.7 ± 7.9 BMI: 38.6 ± 6.0	Metf,Lira, Rofl	12 weeks	Wt,BMI,WC,FI, FBG, HOMA-IR
lensterle et al ³⁴	RCT	Slovenia	Rotterdam	Age: 33.1 ± 6.1 BMI: 37.2±4.5	Met+Lira, Lira	12 weeks	BMI, Wt, WC, FBG,FI, HOMA-IR
lensterle et al ³⁵	RCT	Slovenia	Rotterdam	Age: 34.4 ± 6.5 BMI: 39.0 ± 4.9	Met+Lira,Lira	12 weeks	Wt,BMI, WC, FI,FBG,
lensterle Sever et al ⁷¹	RCT	Slovenia	NIH	Age: 31.3±7.1 BMI: 37.1±4.6	Lira,Metf, Lira+Metf	12 weeks	FBG,BMI,WC,FI,TC,TG,HDL,LDL
ensterle et al ³³	RCT	Slovenia	NIH	Age: 23.5±0.7 BMI: 20.9±0.73	Metf,Rosi	6 months	FBG,FI,BMI, HOMA-IR
ensterle et al ⁷⁰	RCT	Slovenia	NIH	Age: 23.1±3.7 BMI: 29.6 ±6.9	Metf, Rosi	6 months	WC,BMI, FI,FBG,TC, TG, LDL,HDL,HOMA-IR
Kilicdag et al ³⁸	RCT	Turkey	Rotterdam	Age: 24.13 ±1.42 BMI: 26.17 ± 1.44	Metf, Rosi	3 months	BMI, FI,FBG,TC, TG, HOMA-IR
Kocak et al ³⁹	RCT	Turkey	Rotterdam	Age: 26.2 ±3.7 BMI: 31.91± 5.38	Metf, Placebo	2 months	BMI, FI,FBG,WHR
Karimzadeh et al ³⁶	RCT	Iran	Rotterdam	Age: 28.81±3.18 BMI: 29.49±4.7	Metf, placebo	3months	BMI, FI,FBG,TC, TG, HDL,LDL

Kazerooni et al ³⁷	RCT	Iran	Rotterdam	Age: 25.6± 4.32	Metf, simva, placebo	12 weeks	BMI, FI,FBG,TC, TG, HDL,LDL
				BMI: 28.52± 1.61			,.,,,,,
Lam et al ⁴⁰	RCT	China	RoTterdam	Age:N/A	Rosi, placebo	12 months	WC,BMI, FI,FBG,TC, TG,
				BMI:N/A			LDL,HDL,HOMA-IR
i et al ⁴¹	RCT	China	Rotterdam	Age: 25.95± 4.36	Rosi, metformin	6 months	WC,BMI, FI,FBG,TC, TG, WHR, LDL,HDL
				BMI: 27.54 ±2.21			
ingaiah et al ⁴²	RCT	Finland	Rotterdam	Age: 27.6 ±4.0	Metf, placebo	3 months	BMI, FI,FBG, WC ,WHR
				BMI: 26.5 ±6.0			
Liu et al ⁴³	RCT	China	Rotterdam	Age: 27.69 ± 3.80	Metf, Exena	24 weeks	WC,BMI, FI,FBG,TC, TG, WHR, LDL,HD
				BMI: 28.29 ± 1.86			HOMA-IR
∟ord et al ⁷⁸	RCT	UK	N/A	Age: 27.76 ±4.89	Metf, placebo	3 months	WC,BMI, FI,FBG,TC, TG, WHR, LDL,HD
				BMI: 33.74± 6.74			HOMA-IR
Legro et al ⁹¹	RCT	USA	N/A	Age: 28.0 ±4.0	Metf,Rosi	3 months	WC,BMI, FI,FBG, WHR
				BMI: 40.0 ±10.1			
Morin-Papunen et al ⁴⁶	RCT	Finland	Rotterdam	Age: 28.4 ± 3.9	Metf,placebo	3months	Wt, WC,BMI,WHR
				BMI: 27.1 ±6.3			
Morteza Taghavi et al ⁴⁷	RCT	Iran	Rotterdam	Age:N/A	Metf, placebo	6 months	BMI
				BMI:N/A			
Mohiyiddeen et al ⁴⁴	RCT	UK	Rotterdam	Age: 29.0 ±1.0	Metf,Rosig	3 months	WC,BMI, FI,FBG,TC, TG, WHR, LDL,HE
				BMI: 29.7 ±1.0			
Moini et al ⁴⁵	RCT	Iran	Rotterdam	Age: 27.42 ± 3.31	Orlistat, placebo	3 months	BMI, FI,FBG,TC, TG, Wt, LDL,HDL
				BMI: 29.01 ± 2.09			
Muneyyirci-Delale et al48	RCT	USA	Rotterdam	Age:N/A	Metf, spironolactone	12 weeks	BMI,TC, TG,
				BMI:NA			
Mehrabian et al ⁶⁸	RCT	Iran	NIH	Age: 29.18±8.28	Metf, flut, simva	6 months	WC,CRP,BMI,FBG,TG,HDL
				BMI: 29.83±4.1			
Navali et al ⁹⁸	RCT	Iran	N/A	Age:26.43±4.67	Metf, Simva	3 months	BMI, FI,FBG,TC, TG, WHR, LDL,HDL
				BMI:27.71±0.73			
Nemati et al ⁴⁹	RCT	Iran	Rotterdam	Age:N/A	Metf, NAC	12 weeks	BMI,FBG,FI
				BMI: 36.3± 8.4			
Ng et al ⁷⁹	RCT	China	N/A	Age:30.5	Metf, placebo	3 months	BMI,FBG,FI,TC,TG
				BMI:N/A			
Naka et al ⁸⁴	RCT	Greece	N/A	Age: 23.3± 4.9	Metf,Piogl	6 months	WC,BMI, FI,FBG,TC, TG, WHR, LDL,HI
				BMI: 28.7± 5.5			
Ortega-González et al ⁸⁵	RCT	Mexico	N/A	Age: 28.8 ±0.9	Metf, Piogl	6 months	Wt, BMI,WHR
				BMI: 32.2 ±1.0			
Palomba et al ⁸⁰	RCT	Italy	N/A	Age: 24.3 ± 3.1	Metf, Placebo	24 months	BMI,LDL
				BMI: 22.2 ±2.0			
Paredes Palma et al ⁹⁵	RCT	Mixeco	N/A	Age:N/A	Metf, Sitag	N/A	BMI, HOMA-IR
				BMI: N/A			
Penna et al ⁹⁷	RCT	Brazil	N/A	Age: 26.69 ±1.46	Acarbose, Placebo	6 months	BMI

Table2 continued		1		1	1		
Puurunen et al ⁹⁹	RCT	Finland	N/A	Age: 40.5 ±5.9	Atorva, placebo	6 months	BMI, WHR,LDL, HDL
Rautio et al ¹⁰²	RCT	Finland	N/A	BMI: 30.4 ±8.6	Desig placebo	4 months	
Rautio et al ¹⁰²	KCI	Finland	N/A	Age: 29.1 ± 1.2 BMI: 33.1 ± 1.7	Rosig, placebo	4 months	BMI, WHR, Wt
Romualdi et al⁵ ⁰	RCT	Italy	Rotterdam	Age: 24.7 ±4.4	Metf, placebo	Cmantha	BMI,WHR,LDL,HDL,TC
Romualui et al-	KCI	Italy	Rotterdam	BMI: 22.2 ±2.2	Mett, placebo	6 months	BIVII, WHR, LDL, HDL, TC
Rezai et al⁵¹	RCT	Iran	Rotterdam	Age: 26.3±4	Metf, Acarbose	3 months	BMI,FBG,HDL,TG,TC.LDL
	i i i i i i i i i i i i i i i i i i i	Indii	Notteruam	BMI: 26.9 ± 1.8	Wett, Acarbose	5 11011113	bivit, i bo, i be, i o, i c.ebe
Steiner et al ⁹²	RCT	Germany	NIH	Age: 22.9±4.5	Metf, Rosig	6months	BMI,HOMA-IR, FBG,FI
		Germany		BMI: 27.4±6.0	incer, nosig	omontins	
Sova et al ⁵⁴	RCT	Finland	Rotterdam	Age: : 27.7 ±4.0	Metf, placebo	3 months	Wt,WC,WHR,BMI,FBG,FI
				BMI: 27.5 ±6.2			
Shahebrahimi et al⁵³	RCT	Iran	Rotterdam	Age: 27.5 ± 3.68	Metf, piog	3 months	Wt,BMI,WC, FBG, LDL,HDL,TG
				BMI: 27.71±4.36			
Sohrevardi et al ⁸⁶	RCT	Iran	Rotterdam	Age:N/A	Metf,piog, Metf+Piog	3 months	Wt,BMI,WHR,HOMA-IR, FBG, FI
				BMI: 27.5±3.6			
Sathyapalan et al ⁵²	RCT	UK	Rotterdam	Age: 27.7±1.4	Atorvas, placebo	12 weeks	Wt,BMI,WC,WHR,HOMA-IR, FBG,FI
				BMI: 33.20 ±1.4			LDL,TC,TG,HDL
Sönmez et al ⁷²	RCT	Turkey	NIH	Age: 26.13 ±5.08	Metf, Acarbose	3 months	BMI,Wt, FBG,FI
				BMI: 27 ±2.2			
Tao et al ⁵⁵	RCT	China	Rotterdam	Age: 30 ± 5	Saxag, Metf	24 weeks	Wt, BMI,WC,WHR, LDL,HDL,TG, HOMA-IR
				BMI: 27.2		.	
Trolle et al ¹⁰³	RCT	Denmark	N/A	Age: 31	Metf, placebo	6 months	Wt,WHR,FBG,FI,HOMA-IR, LDL,HDL
1	DOT	D I	Detterden	BMI:32			
Underdal et al ⁵⁶	RCT	Denmark	Rotterdam	Age: 29.5 ±3.9 BMI: 28.7± 6.9	Metf, placebo	NA	Wt,BMI,WC,WHR
Vanky et al ⁵⁷	RCT	Norway	Rotterdam	Age: 28.9 ±4.8	Metf, placebo	36 weeks	BMI, DHEAS
Valiky et al	NC1	Norway	Kotteruam	Age: 28.9 ±4.8 BMI: 30.6 ± 7.3	Meti, placebo	SO WEEKS	BIVII, DHEAS
Vandermolen et al ⁸¹	RCT	USA	N/A	Age: 29 6 ±1.2	Metf, Placebo	7 weeks	Wt,BMI, FBG,FI
		0.5/1		BMI: 37.6 ± 4.3		, weeks	
Yarali et al ⁸²	RCT	Turkey	N/A	Age:29.7±5.6	Metf, placebo	6 weeks	WHR,BMI,FBG,FI
				BMI:28.6±4			,
Yilmaz et al ⁵⁸	RCT	Turkey	Rotterdam	Age: 24.67+4.60	Metf, Rosig	24 weeks	FBG,FI,BMI,WHR
				BMI: 27.12+6.18			
Zahra et al ⁵⁹	RCT	Pakistan	Rotterdam	Age: 25.8 ± 6.1	Metf, placebo	3 months	Wt,BMI,FBG,FI,HOMA-IR
				BMI: 26.7 ± 6.5			
Zheng et al ⁶⁰	RCT	China	Rotterdam	Age: 27.70 ± 3.41	Exena, Metf	12 weeks	Wt,BMI,WHR,FBG,FI,HDL,LDL, TG, TC
				BMI: 28.27 ± 4.85			
Ziaee et al ⁶¹	RCT	Iran	Rotterdam	Age: 25.28±4.38	Metf, piog	12 weeks	BMI,HOMA-IR,HDL,LDL,TG,TC
				BMI: 26.13 ±3.03			

RCT: randomised clinical trial, N/A: not available, BMI: body mass index, Wt: weight, WHR: waist hip ratio, WC: waist circumference, FBG: fasting blood glucose, FI: fasting insulin, HDL: high density liporotein, LDL: Low density lipoprotein, TG: triglycerides, TC: total cholesterol, HOMA-IR: homeostatic model of insulin resistance, NIH: national institute for health, NICHD:national inistitute of child health and development. Metf:metformin, Saxa: saxagliptin, Piog: pioglitazone, Rosig: rosiglitazone, Atrova: atorvastatin, Simva:simvastatin, WHO: world health organisation, CRP:C-reactive protein, Lira:liraglutide, USA: united state of America, UK: united kingdom.

Figure 2 : Forest plot of meta-analysis for the effect of various medications on the body weight (kg) compared with placebo

A) Metformin vs Placebo

,										
	Me	tformi	n	Pla	acebo			Mean Difference	Mean Difference	Risk of Bias
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI	ABCDEFG
1.1.1 Metformin 850 m	ng twice	a day								
Gambineri 2004	90.1	14	20	92.9	10.7	20	7.8%	-2.80 [-10.52, 4.92]		•???????
Trolle 2010	94.1	35.9	20	97.3	36.9	20	0.9%	-3.20 [-25.76, 19.36]		?? •?????
Subtotal (95% CI)			40			40	8.7%	-2.84 [-10.15, 4.46]		
Heterogeneity: Tau ² = I	0.00; Chi	² = 0.0	0, df = 1	1 (P = 0.)	97); I ^z	= 0%				
Test for overall effect: 2	Z=0.76 (P = 0.4	5)							
4.4.0 Mattermin 4500										
1.1.2 Metformin 1500										
Eisenhardt 2006	81.3	32	22	85.4	34	22	1.3%			
Heidari 2019	102.3			100.9	19.7	13	1.9%	1.40 [-14.31, 17.11]		
Vandermolen 2001 Zahra 2017	96.9 63.35	8	20	106.9 74.2	6.2	14 20	3.4%	-10.00 [-15.74, -4.26] -10.85 [-22.73, 1.03]		2222242
Subtotal (95% CI)	03.35	12.8	20 82	74.Z	23.9	69	20.2%	-8.74 [-13.50, -3.98]	▲	
Heterogeneity: Tau ² = 1	0.00- Chi	Z = 0.1		2 /P = 0	663-18		20.2/0	-0.14 [-15.50, -5.50]	•	
Test for overall effect: 2				5 (F = 0.	55), 1	- 0 %				
restion overall effect. 2	5.00 (, <u> </u>	,000,							
1.1.3 Metformin 2000	mg a day	y								
Lingaiah 2019	60.4	7.5	40	62.3	8.7	34	29.3%	-1.90 [-5.64, 1.84]		\bullet ? ? ? ? ? ? ?
Morin Papunen 2012	73.5	18	128	76	18	125	21.8%	-2.50 [-6.94, 1.94]	-=+	
Sova 2013	88.6	11	23	89	14.8	27	9.0%	-0.40 [-7.57, 6.77]	-4-	?????
Underdal 2018	82	19.4	66	81.9	18.4	65	10.9%	0.10 [-6.37, 6.57]		???????
Subtotal (95% CI)			257			251	71.0%	-1.62 [-4.08, 0.84]	•	
Heterogeneity: Tau ² = I				3 (P = 0.	.91); I²	= 0%				
Test for overall effect: 2	Z=1.29 (P = 0.2	20)							
Tatal (05% CI)			379			200	400.08	2421522 0.021		
Total (95% CI)							100.0%	-3.13 [-5.33, -0.93]		
Heterogeneity: Tau ² = I				9 (P = 0.	.39); I*	= 5%			-50 -25 0 25 50	
Test for overall effect: 2 Test for subgroup diffe			/	(_) (D.	- 0.00	12 - 71	- en/		Favours [Metformin] Favours [Placebo]	
rescior subgroup alme	rences: (Unif = I	o.au, a	I = 2 (P :	= 0.03)	, i= <i>1</i> 1	0.070			

B) Rosiglitazone vs placebo

Rosiglitazone Placebo Mean Difference Mean Difference Risk of Bias													
Study or Subgroup	Mean		Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl	ABCDEFG			
3.1.1 Rosiglitazone 4	mg vs P	lacebo											
Batista 2012	68.15	15.29	16	72.45	16.63	17	28.0%	-4.30 [-15.19, 6.59]		• ? ? ? ? ? ? ?			
Lam 2011	62	12.7882	24	64.2	17.4073	30	51.0%	-2.20 [-10.26, 5.86]	, •				
Subtotal (95% CI)			40			47	79.0%	-2.94 [-9.42, 3.54]	•				
Heterogeneity: Tau ² =	0.00; Ch	ni² = 0.09,	df = 1 (P = 0.76	5); I ² = 0%								
Test for overall effect:	Z = 0.89	(P = 0.37)											
3.1.2 Rosiglitazone 2	-	-		-									
Cataldo 2006	100.8	24.3998		109.7	10	72	21.0%						
Subtotal (95% CI)			15			72	21.0%	-8.90 [-21.46, 3.66]					
Heterogeneity: Not ap													
Test for overall effect:	Z=1.39	(P = 0.16)											
Total (95% CI)			55			110	100.0%	-4.19 [-9.95, 1.56]					
	0.00.06	2 - 0 77		n – o ei	N 17 - 00	119	100.0%	-4.19 [-9.95, 1.50]		_			
Heterogeneity: Tau ² = Test for overall effect:				P = 0.68	5), 17 = 0%				-100 -50 Ó 50 1ÓO				
Test for subgroup diff				1 /P = (1411 18-0	106			Favours [Rosiglitazone] Favours [Placebo]				
Risk of bias legend	elences.	. Oni = 0.0	50, ui -	1 (F = 0	.41),1 - C	1 70							
(A) Random sequence		ation (colo	ction b	ioo)									
(B) Allocation conceal	-			145)									
(C) Blinding of particip				formon	o bioc)								
(D) Blinding of outcon					e uids)								
(E) Incomplete outcor				10103)									
(F) Selective reporting	-		as)										
(G) Other bias	(icpoint)	ig blas/											
(a) other bids													

Figure 3: Forest plot of meta-analysis for the effect of various medications on the BMI (kg/m²) compared with placebo

A) Metformin vs Placebo

	Met	formin		Pla	acebo			Mean Difference	Mean Difference	Risk of Bias
tudy or Subgroup	Mean			Mean		Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI	ABCDEFG
.2.1 Metformin 850 m	-									
heng 2016	24.3	5	44	24.5	4.5	13	1.9%	-0.20 [-3.06, 2.66]		
∂ambineri 2004	34.1	6	20	35.4	4	20	1.5%	-1.30 [-4.46, 1.86]		• ? ? ? ? ? ? ?
Kocak 2002	30.47		27	31.1	3.5	28	2.7%	-0.63 [-3.00, 1.74]		• ? ? ? ? ? ? ?
/arali 2002	28	3.4	16	29.8	4.9	16	1.8%	-1.80 [-4.72, 1.12]		•???????
Subtotal (95% CI)			107			77	8.0%	-0.92 [-2.31, 0.47]	-	
leterogeneity: Tau² = (est for overall effect: Z				(P = 0.)	87); F÷	= 0%				
.2.2 Metformin 1500	mg/day fo	or 3 mo	nths							
Chou 2003	34.9	5	14	37.2	6.4	16	0.9%	-2.30 [-6.39, 1.79]		2000022
Eisenhardt 2006	31.1	17	32	32.4		22	0.2%	-1.30 [-10.62, 8.02]		• • • • • • • • • • • • • • • • • • • •
leidari 2019	36.2		29	37.7	8.1	13	0.5%	-1.50 [-7.28, 4.28]		
arimzadeh 2007	28.45	2.8		29.29	4.8	100	12.9%	-0.84 [-1.93, 0.25]		$\bullet \bullet \bullet \bullet \bullet \bullet ? ?$
(azerooni 2010	26.31			27.07		42	33.8%	-0.76 [-1.43, -0.09]	-=1	
ingaiah 2019	32.9	4.4	17	33.3	4.5	27	2.1%	-0.40 [-3.09, 2.29]		• ? ? ? ? ? ? ?
ord 2006	34.6			35.26		15	0.5%	-0.66 [-6.22, 4.90]		•••••
lorin Papunen 2012	26.9	6.2	160	27.7	6.2	160	8.3%	-0.80 [-2.16, 0.56]		
lg 2001		18.4	8	23.1	15	7		-0.10 [-17.01, 16.81]	•	\rightarrow \bullet $?$ $?$ $?$ $?$ $?$ $?$ $?$ $?$
lova 2013	32.9	3.8	23	32.9	4.8	27	2.7%	0.00 [-2.39, 2.39]		???? + ??
ahra 2017 ubtotal (95% CI)	25.3	5.7	20 461	29.7	9.7	20 449	0.6% 62.6%	-4.40 [-9.33, 0.53]		??????
ubtotal (95% Cl) leterogeneity: Tau² = (est for overall effect: Z			df = 1	0 (P = 0).98); F		02.0%	-0.80 [-1.30, -0.31]	•	
2.3 Metformin 1500										
				20.2	26	26	2701	-0.201.2.70.2.401		
miri 2014 IortezaTaghavi 2011	28.9 28.59	5 2.56	25 15	29.2 27.96	3.6	26 12	2.7% 5.8%	-0.30 [-2.70, 2.10] 0.63 [-0.99, 2.25]		2222222
ubtotal (95% CI)	26.99	2.56	15 40	27.90	1.73	38	5.8% 8.5%	0.63 [-0.99, 2.25] 0.34 [-1.01, 1.68]	—	*******
leterogeneity: Tau² = (est for overall effect: Z				(P = 0.)	53); I²:	= 0%				
.2.4 Metformin 1700	mg/day fo	or 12 m	onths							
alomba 2007	22.4	2	14	22.6	1.9	13	7.1%	-0.20 [-1.67, 1.27]		
Subtotal (95% CI)			14			13	7.1%	-0.20 [-1.67, 1.27]		
leterogeneity: Not app 'est for overall effect: Z		2 = 0 79	,							
	c = 0.27 (i	0.10	/							
.2.5 Metformin 1000										
Romualdi 2010		or 6 mo	nths 13	23.3	4.1	10	1.8%	-1.20 [-4.09, 1.69]		
omualdi 2010	mg/day fo	or 6 mo	nths	23.3	4.1	10 10	1.8% 1.8%	-1.20 [-4.09, 1.69] - 1.20 [-4.09, 1.69]	-	
omualdi 2010 ubtotal (95% CI) eterogeneity: Not app	mg/day fo 22.1 olicable	o r 6 mo 2.52	nths 13 13	23.3	4.1				•	
omualdi 2010 ubtotal (95% CI) leterogeneity: Not app est for overall effect: 2	mg/day fo 22.1 olicable Z = 0.81 (F	2.52 9 = 0.42	nths 13 13 13	23.3	4.1				-	
Romualdi 2010 Subtotal (95% CI) Reterogeneity: Not app rest for overall effect: 2 .2.6 Metformin 1500 (andermolen 2001	mg/day fo 22.1 olicable Z = 0.81 (F	2.52 9 = 0.42	nths 13 13 13) eks 11	23.3 38.4	4.1	10 14	1.8% 3.4%	- 1.20 [4.09, 1.69] -3.00 [-5.11, -0.89]		•••••
omualdi 2010 ubtotal (95% CI) eterogeneity: Not app est for overall effect: 2 2.6 Metformin 1500 andermolen 2001 ubtotal (95% CI)	mg/day fo 22.1 blicable Z = 0.81 (F mg/day fo 35.4	or 6 moi 2.52 P = 0.42 or 7 wee	nths 13 13 13) eks			10	1.8%	-1.20 [-4.09, 1.69]	• •	
omualdi 2010 ubtotal (95% CI) eterogeneity: Not app est for overall effect: 2 2.6 Metformin 1500 andermolen 2001 ubtotal (95% CI) eterogeneity: Not app	mg/day fo 22.1 olicable Z = 0.81 (F mg/day fo 35.4 olicable	2.52 P = 0.42 or 7 we 3.1	nths 13 13 13) eks 11 11			10 14	1.8% 3.4%	- 1.20 [4.09, 1.69] -3.00 [-5.11, -0.89]	•	
tomualdi 2010 ubtotal (95% CI) leterogeneity: Not app est for overall effect: 2 .2.6 Metformin 1500 andermolen 2001 ubtotal (95% CI) leterogeneity: Not app est for overall effect: 2 .2.7 Metformin 850 m	mg/day fo 22.1 olicable Z = 0.81 (F mg/day fo 35.4 olicable Z = 2.79 (F	or 6 moi 2.52 P = 0.42 or 7 wea 3.1 P = 0.00	nths 13 13) eks 11 11 5)	38.4	2	10 14 14	1.8% 3.4% 3.4%	- 1.20 [4.09, 1.69] -3.00 [-5.11, -0.89]	•	• 3 3 3 • 3 3
Romualdi 2010 Subtotal (95% CI) Fest for overall effect: 2 .2.6 Metformin 1500 (Yandermolen 2001 Subtotal (95% CI) Fest for overall effect: 2 .2.7 Metformin 850 m Yanky 2004a	mg/day fo 22.1 olicable Z = 0.81 (F mg/day fo 35.4 olicable Z = 2.79 (F ng BID for	or 6 moi 2.52 P = 0.42 or 7 wea 3.1 P = 0.00	nths 13 13) eks 11 11 5)	38.4 :hange	2	10 14 14	1.8% 3.4% 3.4%	- 1.20 [4.09, 1.69] -3.00 [-5.11, -0.89]		
omualdi 2010 ubtotal (95% CI) eterogeneity: Not app est for overall effect: 2 2.6 Metformin 1500 : andermolen 2001 ubtotal (95% CI) eterogeneity: Not app est for overall effect: 2 2.7 Metformin 850 m anky 2004a ubtotal (95% CI) eterogeneity: Not app	mg/day fo 22.1 2licable Z = 0.81 (F mg/day fo 35.4 2licable Z = 2.79 (F ng BID for 2.4 2licable	or 6 moi 2.52 P = 0.42 or 7 wea 3.1 P = 0.00 - 36 moi 2.1	nths 13 13) eks 11 11 5) nths-c 16 16	38.4 :hange	2 from l	10 14 14 0aselin 17	1.8% 3.4% 3.4% 8.6%	-1.20 [-4.09, 1.69] -3.00 [-5.11, -0.89] -3.00 [-5.11, -0.89] -0.80 [-2.14, 0.54]	•	• 3 3 3 • 3 3
omualdi 2010 ubtotal (95% CI) eterogeneity: Not app est for overall effect: 2 2.6 Metformin 1500 (andermolen 2001 ubtotal (95% CI) eterogeneity: Not app est for overall effect: 2 2.7 Metformin 850 m anky 2004a ubtotal (95% CI) eterogeneity: Not app est for overall effect: 2	mg/day fo 22.1 2licable Z = 0.81 (F mg/day fo 35.4 2licable Z = 2.79 (F ng BID for 2.4 2licable	or 6 moi 2.52 P = 0.42 or 7 wea 3.1 P = 0.00 - 36 moi 2.1	nths 13 13) eks 11 11 5) nths-c 16 16	38.4 :hange	2 from l	10 14 14 0aselin 17 17	1.8% 3.4% 3.4% 8.6% 8.6%	-1.20 [-4.09, 1.69] -3.00 [-5.11, -0.89] -3.00 [-5.11, -0.89] -0.80 [-2.14, 0.54] -0.80 [-2.14, 0.54]		• 3 3 3 • 3 3
tomualdi 2010 ubtotal (95% CI) leterogeneity: Not app est for overall effect: 2 .2.6 Metformin 1500 andermolen 2001 ubtotal (95% CI) leterogeneity: Not app est for overall effect: 2 .2.7 Metformin 850 m anky 2004a ubtotal (95% CI) leterogeneity: Not app est for overall effect: 2 otal (95% CI)	mg/day fo 22.1 Dilicable Z = 0.81 (F mg/day fo 35.4 Dilicable Z = 2.79 (F 2.4 Dilicable Z = 1.17 (F	or 6 moi 2.52 P = 0.42 or 7 wea 3.1 P = 0.00 c 36 moi 2.1 P = 0.24	nths 13 13) eks 11 5) 5) nths-c 16 16 16 0	38.4 :hange 3.2	2 from I 1.8	10 14 14 0aselin 17 17 618	1.8% 3.4% 3.4% e 8.6% 8.6% 100.0%	-1.20 [-4.09, 1.69] -3.00 [-5.11, -0.89] -3.00 [-5.11, -0.89] -0.80 [-2.14, 0.54]		• 3 3 3 • 3 3
Romualdi 2010 Jubtotal (95% CI) Jeterogeneity: Not app jest for overall effect: 2 .2.6 Metformin 1500 Jandermolen 2001 Jubtotal (95% CI) Jeterogeneity: Not app jest for overall effect: 2 .2.7 Metformin 850 m Janky 2004a Jubtotal (95% CI) Jeterogeneity: Not app jest for overall effect: 2 Jotal (95% CI) Jeterogeneity: Tau ² = (mg/day fc 22.1 olicable Z = 0.81 (F mg/day fc 35.4 olicable Z = 2.79 (F ng BID for 2.4 olicable Z = 1.17 (F	r 6 moi2.52 $r = 0.42r 7 we3.1r = 0.00r 36 moi2.1r = 0.24r = 0.24$	nths 13 13) eks 11 5) 5) 16 16 16 0) 662 0, df =	38.4 :hange 3.2	2 from I 1.8	10 14 14 0aselin 17 17 618	1.8% 3.4% 3.4% e 8.6% 8.6% 100.0%	-1.20 [-4.09, 1.69] -3.00 [-5.11, -0.89] -3.00 [-5.11, -0.89] -0.80 [-2.14, 0.54] -0.80 [-2.14, 0.54]		• ? ? ? • ? ? • • ? ? • • •
Romualdi 2010 Jubtotal (95% CI) Jeterogeneity: Not app jest for overall effect: 2 .2.6 Metformin 1500 (andermolen 2001 Jeterogeneity: Not app jest for overall effect: 2 .2.7 Metformin 850 m Sanky 2004a Jubtotal (95% CI) Jeterogeneity: Not app jest for overall effect: 2 otal (95% CI) Jeterogeneity: Tau ² = (jest for overall effect: 2 otal (95% CI)	mg/day fc 22.1 olicable Z = 0.81 (F mg/day fc 35.4 olicable Z = 2.79 (F ng BID for 2.4 olicable Z = 1.17 (F 0.00; Chi ⁼ Z = 3.78 (F	or 6 moi 2.52 P = 0.42 or 7 wea 3.1 P = 0.00 36 moi 2.1 P = 0.24 P = 0.24 P = 11.90 P = 0.00	nths 13 13 13) eks 11 11 5) nths-c 16 16 16) 662 0), df = 02)	38.4 :hange 3.2 20 (P =	2 from I 1.8 0.92);	10 14 14 17 17 17 618 I ² = 0%	1.8% 3.4% 3.4% 8.6% 8.6%	-1.20 [-4.09, 1.69] -3.00 [-5.11, -0.89] -3.00 [-5.11, -0.89] -0.80 [-2.14, 0.54] -0.80 [-2.14, 0.54]	-10 -5 0 5 Favours (Metformin) Favours (Plac	• ? ? ? • ? ? • • ? ? • • •
Romualdi 2010 Subtotal (95% CI) Heterogeneity: Not app Test for overall effect: 2 (.2.6 Metformin 1500 f (andermolen 2001 Subtotal (95% CI) Heterogeneity: Not app Test for overall effect: 2 Subtotal (95% CI) Heterogeneity: Not app Test for overall effect: 2 Total (95% CI) Heterogeneity: Tau ² = (Test for overall effect: 2 Test for overall effect: 2	mg/day fc 22.1 olicable Z = 0.81 (F mg/day fc 35.4 olicable Z = 2.79 (F ng BID for 2.4 olicable Z = 1.17 (F 0.00; Chi ⁼ Z = 3.78 (F	or 6 moi 2.52 P = 0.42 or 7 wea 3.1 P = 0.00 36 moi 2.1 P = 0.24 P = 0.24 P = 11.90 P = 0.00	nths 13 13 13) eks 11 11 5) nths-c 16 16 16) 662 0), df = 02)	38.4 :hange 3.2 20 (P =	2 from I 1.8 0.92);	10 14 14 17 17 17 618 I ² = 0%	1.8% 3.4% 3.4% 8.6% 8.6%	-1.20 [-4.09, 1.69] -3.00 [-5.11, -0.89] -3.00 [-5.11, -0.89] -0.80 [-2.14, 0.54] -0.80 [-2.14, 0.54]		• ? ? ? • ? ? • • ? ? • • •
I.2.5 Metformin 1000 I Romualdi 2010 Subtotal (95% CI) Heterogeneity: Not app Fest for overall effect: 2 I.2.6 Metformin 1500 I /andermolen 2001 Subtotal (95% CI) Heterogeneity: Not app Fest for overall effect: 2 I.2.7 Metformin 850 m /anky 2004a Subtotal (95% CI) Heterogeneity: Not app Fest for overall effect: 2 Fotal (95% CI) Heterogeneity: Tau ² = (Fest for overall effect: 2 Fotal (95% CI)	mg/day fc 22.1 blicable Z = 0.81 (F mg/day fc 36.4 blicable Z = 2.79 (F 2.4 blicable Z = 1.17 (F 0.00; Chi ² Z = 3.78 (F rences: C	or 6 moi 2.52 or 7 wea 3.1 or 7 wea 2.1 or 7 wea 3.1 or 7	nths 13 13 13) eks 11 11 5) 5) 16 16 16 16 02 02 62, df	38.4 thange 3.2 20 (P = = 6 (P =	2 from I 1.8 0.92);	10 14 14 17 17 17 618 I ² = 0%	1.8% 3.4% 3.4% 8.6% 8.6%	-1.20 [-4.09, 1.69] -3.00 [-5.11, -0.89] -3.00 [-5.11, -0.89] -0.80 [-2.14, 0.54] -0.80 [-2.14, 0.54]		• ? ? ? • ? ? • • ? ? • • •
Romualdi 2010 Subtotal (95% CI) Heterogeneity: Not app Fest for overall effect: 2 (.2.6 Metformin 1500 (Andermolen 2001 Subtotal (95% CI) Heterogeneity: Not app Fest for overall effect: 2 (.2.7 Metformin 850 m Yanky 2004a Subtotal (95% CI) Heterogeneity: Not app Fest for overall effect: 2 Fotal (95% CI) Heterogeneity: Tau ^a = 0 Fest for subgroup diffe Fest for subgroup diffe Fest for subgroup diffe Fest for subgroup diffect: 2	mg/day fc 22.1 olicable Z = 0.81 (F mg/day fc 35.4 olicable Z = 2.79 (F ng BID for 2.4 olicable Z = 1.17 (F 0.00; Chi ² Z = 3.78 (F prences: C e generati	or 6 moi 2.52 P = 0.42 or 7 wea 3.1 P = 0.00 7 36 moi 2.1 2 36 moi 2 36 moi 2 1 2 1 2 6 moi 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 3 1	nths 13 13 13) eks 11 11 5) nths-c 16 16 16 0, df = 02) 62, df ection	38.4 thange 3.2 20 (P = = 6 (P =	2 from I 1.8 0.92);	10 14 14 17 17 17 618 I ² = 0%	1.8% 3.4% 3.4% 8.6% 8.6%	-1.20 [-4.09, 1.69] -3.00 [-5.11, -0.89] -3.00 [-5.11, -0.89] -0.80 [-2.14, 0.54] -0.80 [-2.14, 0.54]		• ? ? ? • ? ? • • ? ? • • •
Romualdi 2010 Subtotal (95% CI) Heterogeneity: Not app Fest for overall effect: 2 (J.2.6 Metformin 1500 i /andermolen 2001 Subtotal (95% CI) Heterogeneity: Not app Fest for overall effect: 2 (J.2.7 Metformin 850 m /anky 2004a Subtotal (95% CI) Heterogeneity: Not app Fest for overall effect: 2 Fotal (95% CI) Heterogeneity: Tau ² = 0 Fest for subgroup diffe Risk of bias legend A) Random sequence B) Allocation concealn	mg/day fc 22.1 olicable Z = 0.81 (F mg/day fc 35.4 olicable Z = 2.79 (F 2.4 olicable Z = 1.17 (F 2.4 olicable Z = 1.17 (F 2.4 olicable Z = 3.78 (F rences: C e generati ment (sele	or 6 moi 2.52 P = 0.42, or 7 wee 3.1 P = 0.00 r 36 moi 2.1 P = 0.24, r = 11.90 P = 0.24, r = 0.00 Chi = 7,1 on (sele	nths 13 13 13) eks 11 11 5) nths-c 16 16 16 02) 662, df ection ias)	38.4 thange 3.2 20 (P = = 6 (P = bias)	2 from I 1.8 0.92); = 0.27)	10 14 14 14 17 17 618 618 618 (² = 0%	1.8% 3.4% 3.4% 8.6% 8.6%	-1.20 [-4.09, 1.69] -3.00 [-5.11, -0.89] -3.00 [-5.11, -0.89] -0.80 [-2.14, 0.54] -0.80 [-2.14, 0.54]		• ? ? ? • ? ? • • ? ? • • •
Romualdi 2010 Subtotal (95% CI) Heterogeneity: Not app Fest for overall effect: 2 (.2.6 Metformin 1500 i /andermolen 2001 Subtotal (95% CI) Heterogeneity: Not app Fest for overall effect: 2 (.2.7 Metformin 850 m /anky 2004a Subtotal (95% CI) Heterogeneity: Not app Fest for overall effect: 2 Fotal (95% CI) Heterogeneity: Tau ² = (Fest for overall effect: 2 Fest for overall effect for overall effect for overall effect for	mg/day fc 22.1 olicable Z = 0.81 (F mg/day fc 35.4 olicable Z = 2.79 (F ng BID for 2.4 olicable Z = 1.17 (F 0.00; Chi ² Z = 3.78 (F erences: C e generati ment (sele ants and f	or 6 moi 2.52 P = 0.42 or 7 wea 3.1 P = 0.00 r 36 moi 2.1 P = 0.24 2 = 11.90 P = 0.00 Chi = 7.1 con (sele ection (sele personr	nths 13 13 13) eks 11 11 5) 5) 65 16 16 0, df = 02) 662 df ection ias) nel (pe	38.4 hange 3.2 20 (P = = 6 (P = bias) erformal	2 from I 1.8 0.92); : 0.27) nce bia	10 14 14 14 17 17 618 618 618 (² = 0%	1.8% 3.4% 3.4% 8.6% 8.6%	-1.20 [-4.09, 1.69] -3.00 [-5.11, -0.89] -3.00 [-5.11, -0.89] -0.80 [-2.14, 0.54] -0.80 [-2.14, 0.54]		• ? ? ? • ? ? • • ? ? • • •
Romualdi 2010 Subtotal (95% CI) Heterogeneity: Not app Test for overall effect: 2 (.2.6 Metformin 1500 f Andermolen 2001 Subtotal (95% CI) Heterogeneity: Not app Test for overall effect: 2 Subtotal (95% CI) Heterogeneity: Not app Test for overall effect: 2 Fotal (95% CI) Heterogeneity: Tau ² = (Total (95% CI) Heterogeneity: Tau ² = (Test for overall effect: 2 Test f	mg/day fc 22.1 olicable Z = 0.81 (F mg/day fc 35.4 olicable Z = 2.79 (F ng BID for 2.4 olicable Z = 1.17 (F c.4) olicable Z = 3.78 (F rences: C e generati ment (sele ants and p e assess	or 6 moi 2.52 P = 0.42 or 7 wea 3.1 P = 0.00 r 36 moi 2.1 P = 0.24 P = 0.24 P = 0.00 Chi² = 7.1 on (selection bippersonr ment (d	nths 13 13) eks 11 11 5) nths-c 16 16 16 16 02 02 62, df ection ias) ectionel (pe letecti	38.4 hange 3.2 20 (P = = 6 (P = bias) erformal	2 from I 1.8 0.92); : 0.27) nce bia	10 14 14 14 17 17 618 618 618 (² = 0%	1.8% 3.4% 3.4% 8.6% 8.6%	-1.20 [-4.09, 1.69] -3.00 [-5.11, -0.89] -3.00 [-5.11, -0.89] -0.80 [-2.14, 0.54] -0.80 [-2.14, 0.54]		• ? ? ? • ? ? • • ? ? • • •
Romualdi 2010 Subtotal (95% CI) Heterogeneity: Not app Test for overall effect: 2 	mg/day fc 22.1 olicable Z = 0.81 (F mg/day fc 35.4 olicable Z = 2.79 (F ng BID for 2.4 olicable Z = 1.17 (F 0.00; Chi ² Z = 3.78 (F prences: C e generati ment (sele ants and p e assess ne data (at	P = 0.42 P = 0.42 r 7 weat $3.1P = 0.00r 36 mot 2.1P = 0.24r = 11.90P = 0.00hi^2 = 7.1ion (selection bipersonn ment (dttrition b$	nths 13 13) eks 11 11 5) nths-c 16 16 16 16 02 02 62, df ection ias) ectionel (pe letecti	38.4 hange 3.2 20 (P = = 6 (P = bias) erformal	2 from I 1.8 0.92); : 0.27) nce bia	10 14 14 14 17 17 618 618 618 (² = 0%	1.8% 3.4% 3.4% 8.6% 8.6%	-1.20 [-4.09, 1.69] -3.00 [-5.11, -0.89] -3.00 [-5.11, -0.89] -0.80 [-2.14, 0.54] -0.80 [-2.14, 0.54]		• ? ? ? • ? ? • • ? ? • • •

Table 3: summary pooled effect estimates of various medications on body weight, BMI, WC, and WHR in women with PCOS

Intervention	Comparison	No of women in the intervention arm	No of women in the control arm	No of RCTs	Pooled effect estimates	95% CI	l² (%)	l² (p value)	Overall effect (p- value*)
		Outcome: me	an body we	ight in k	kilograms (Kg)			
		Rosi	glitazone v	s metfor	min				
Rosiglitazone 4 mg QD	Metformin 850 mg BID for 3 months	15	15	1	0.35	-2.58-3.28	-	-	-
Rosiglitazone 4 mg QD	Metformin 1500 mg QD for 6 months	67	68	1	3.19	0.65-5.73	-	-	-
Rosiglitazone 4 mg QD	Metformin 2000 mg QD for 4 months	14	33	1	1.83	-6.62- 10.28	-	-	-
Overall: Rosiglitazone ve	rsus Metformin	96	116	3	1.95	0.03-3.87	3.0	0.36	0.05
			f						
Metformin 850 mg BID for 6 months	Pioglitazone 45 mg QD	33	formin vs p 31	2 2	one -1.66	-3.19-0.59	0.0	0.56	
Metformin 1500 mg QD for 3 months	Pioglitazone 45 mg QD	50	51	2	-1.45	-6.40-3.51	0.0	0.90	0.42
Overall: Metformin versu	us Pioglitazone	83	82	4	-1.62	-3.67-0.43	0.0	0.95	0.12
		1:		matform	-1-				
Liraglutide 1.2 mg QD for 12 weeks	Metformin 1000 mg QD for 12 weeks	42	aglutide vs 27	2	2.17	-10.66- 14.99	51	0.15	0.74
Liraglutide 1.2 mg QD for 12 weeks	Liraglutide 1.2 mg QD with Metformin 1000 mg QD for 12 weeks	46	47	3	3.30	-2.95-9.54	0.0	0.59	0.30
		N	1etformin v	e orlista	.+				
Metformin 1500 mg QD for 3 months	Orlistat 120 mg tds	60	61	3	-3.28	-7.29-0.74	58	0.09	0.11
				n otfer			1	I	
Exenatide 10 µg BID	Metformin 1000 mg BID for 12 weeks	109	enatide vs i	2	0.22	-2.01-2.44	0.0	0.51	0.85
		Outcome: n	nean BMI ir	n kg/m²					
		Metformi	n vs pioglita	azone					
Metformin 850 mg BID for 6 months	Pioglitazone	33	31	2	-1.07	-2.02-0.12	0.0	0.80	-

	TT		1		1			1	
Metformin 1500 mg QD for 3 months	Pioglitazone	86	86	4	-0.69	-1.78-0.41	0.0	0.55	-
Overall: Metformin vers	us Pioglitazone	119	117	6	-0.91	-1.62-0.19	0.0	0.78	0.01
		Rosi	glitazone v	<mark>s metfo</mark>	r <mark>min</mark>				
Rosiglitazone 4 mg QD	Metformin 850 mg BID	154	133	6	0.22	-1.33-1.77	0.0	0.73	-
Rosiglitazone 4 mg QD	Metformin 1000 mg QD	18	17	1	1.38	0.76-2.0	-	-	-
Rosiglitazone 4 mg QD	Metformin 1500 mg QD	67	69	1	0.33	-0.37-1.03	-	-	-
Rosiglitazone 4 mg QD	Metformin 2000 mg QD	23	39	2	-0.32	-2.78-2.14	0.0	0.82	-
Overall: Rosiglitazone ve	ersus Metformin	262	358	10	<mark>0.80</mark>	<mark>0.32-1.27</mark>	<mark>3.0</mark>	<mark>0.41</mark>	0.001
		Sitaglipti	n + metfori	nin vs n	netformin				
Sitagliptin 100 mg QD with Metformin 850 mg BID	Metformin 850 mg BID	5	5	1	-2.00	-10.87- 6.87	-	-	-
Sitagliptin 100 mg QD with Metformin 1000 mg BID	Metformin 1000 mg BID	12	12	1	-4.40	-8.69-0.11	-	-	-
Overall: Sitagliptin plus Metformin	Metformin versus	17	17	2	-3.94	-7.81-0.08	0.0	0.63	0.05
		Exenatio	le vs metfo	rmin					
Exenatide 10 μg BID	Metformin 1000 mg BID for 12 weeks	31	32	1	-1.15	-3.47-1.17	-	-	-
Exenatide 10 µg BID	Metformin 1000 mg BID for 24 weeks	92	94	2	-0.68	-1.88-0.52	51	0.15	-
Overall: Exenatide versu	ıs Metformin	123	126	3	-0.85	-1.61-0.08	6	0.35	0.03
		Ad	carbose vs i	metform	nin				
Acarbose 100 mg QD for 3 months	Metformin	30	30	1	-1.30	-2.40-0.20	-	-	-
Acarbose 300 mg QD for 3 months	Metformin	44	42	2	-1.18	-2.63-0.27	0.0	0.56	-
Overall: Acarbose versus	s Metformin	74	72	3	-1.26	-2.13-0.38	0.0	0.84	0.005
		Lir	aglutide vs	metforr	nin	•			•

Liraglutide 1.2 mg QD	Metformin 1000 mg BID for 12 weeks	42	21	2	3.09	-1.11-7.29	4.0	0.31	0.23
Liraglutide 1.2 mg QD for 12 weeks	Liraglutide 1.2 mg QD with Metformin 1000 mg QD for 12 weeks	46	47	3	0.74	-1.27-2.74	0.0	0.53	0.47
		c	Orlistat vs m	etformi	'n				
Orlistat 120 mg tds	Metformin 1500 mg QD for 3 months	55	55	2	0.04	-4.18-4.26	93	0.0002	0.87
		Spiro	onolactone	vs metfo	ormin				
Spironolactone 50 mg QD	Metformin 1500 mg QD for 12 weeks	12	24	1	0.47	-1.02-1.97	-	-	-
Spironolactone 50 mg QD	Metformin 1000 mg QD for 6 months	85	153	2	0.04	-0.88-0.96	0.0	0.89	-
Overall: Spironolactone	versus Metformin	97	177	3	0.16	-0.62-0.94	0.0	0.88	0.69
		Sa	xagliptin vs	metform	nin	-			
Saxagliptin 5 mg QD	Metformin 2000 mg QD for 24 weeks	21	21	1	1.36	-1.39-4.11	-	-	-
Saxagliptin 5 mg QD	Metformin 2000 mg QD for 16 weeks	11	12	1	0.00	-7.44-7.44	-	-	-
Overall: Saxagliptin vers	us Metformin	32	33	2	1.20	-1.38-3.78	0.0	0.74	0.36
		Me	etformin vs	simvast	atin				
Metformin 1000 mg QD	Simvastatin 20 mg QD for 6 months	34	34	1	-0.21	-2.15-1.73	-	-	-
Metformin 1500 mg QD	Simvastatin 20 mg QD for 3 months	100	100	1	-0.08	-1.46-1.30	-	-	-
Overall: Metformin vers	us Simvastatin	134	134	2	-0.12	-1.25-1.00	0.0	0.91	0.83
			Metformin	vs NAC					
Metformin 1500 mg QD	NAC 1800 mg QD for 12 weeks	54	54	1	-4.10	-6.63-1.57	-	-	-
Metformin 1500 mg QD	NAC 600 mg tds for 24 weeks	48	46	1	1.25	0.04-2.46	-	-	-

Overall: Metformin vers	us NAC	102	100	2	-1.30	-6.54-3.93	93	0.0002	0.63
	Ou	tcome: mean w	vaist circum	ference	in cm				
		Metformi	n vs pioglit	azone					
Metformin 1500 mg QD	Pioglitazone 30 mg QD for 3 months	28	28	1	-0.45	-5.42-4.52	-	-	-
Metformin 850 mg BID	Pioglitazone 30 mg QD for 6 months	15	14	1	0.30	-8.94-9.54	-	-	-
Overall: Metformin vers	us Pioglitazone	43	42	2	-0.28	-4.66-4.10	0.0	0.98	0.90
		Lira	aglutide vs	metforn	nin				
Liraglutide 1.2 mg QD for 12 weeks	Metformin 1000 mg BID for 12 weeks	28	27	2	-3.66	-14.84- 7.52	49	0.16	0.52
Liraglutide 1.2 mg QD for 12 weeks	Liraglutide 1.2 mg QD with Metformin 1000 mg QD for 12 weeks	46	47	3	3.34	-2.61-9.29	0.0	0.94	0.27
		Rosi	iglitazone v	s metfor	rmin				
Rosiglitazone 4 mg QD	Metformin 1500 mg QD	67	67	1	-0.04	-2.43-2.35	-	-	-
Rosiglitazone 4 mg QD	Metformin 850 mg BID	58	56	1	-0.68	-6.07-4.70	-	-	-
Rosiglitazone 4 mg QD	Metformin 2000 mg QD	6	99	1	0.80	-6.30-7.90	-	-	-
Overall: Rosiglitazone ve	ersus Metformin	131	222	3	-0.06	-2.15-2.03	0.0	0.98	0.95
		Sax	kagliptin vs	metform	nin				
Saxagliptin 5 mg QD	Metformin 2000 mg QD for 12 weeks	21	21	1	2.80	-0.29-5.89	-	-	-
Saxagliptin 5 mg QD	Metformin 2000 mg QD for 16 weeks	11	12	1	-3.00	-14.98- 8.98	-	-	-
Overall: Saxagliptin vers	us Metformin	32	33	2	2.44	-0.55-5.43	0.0	0.36	0.11
		Outcon	ne: mean W	/HR					

		Ex	enatide vs ı	metform	nin					
Exenatide 10 μg BID	Metformin 1000 mg BID for 24 weeks	78	80	1	-0.02	-0.04-0.00	-	-	-	
Exenatide 10 μg BID	Metformin 1000 mg BID for 12 weeks	31	32	1	-0.01	-0.05-0.03	-	-	-	
Overall: Exenatide versu	s Metformin	109	112	2	-0.02	-0.04-0.00	0.0	0.67	0.56	
		Spiro	nolactone	vs metfo	ormin					
Spironolactone 50 mg QD	Metformin 1000 mg QD for 6 months	85	153	2	0.03	0.01-0.05	0.0	0.33	0.96	
		Met	tformin vs p	pioglitaz	one					
Metformin 1500 mg QD for 3 months	Pioglitazone 30 mg for 3 months	22	23	1	0.02	-0.01-0.05	-	-	-	
Metformin 850 mg BID for 6 months	Pioglitazone 30 mg for 3 months	33	31	2	0.01	-0.03-0.05	0.0	0.96	-	
Overall: Metformin versus Pioglitazone		55	54	3	0.02	-0.00-0.04	0.0	0.93	0.12	
		Rosi	glitazone v	s metfoi	min					
Rosiglitazone 4 mg QD	Metformin 1500 mg QD	67	68	1	0.01	-0.01-0.03	-	-	-	
Rosiglitazone 4 mg QD	Metformin 850 mg BID	45	43	1	0.00	-0.03-0.03	-	-	-	
Overall: Rosiglitazone ve	ersus Metformin	112	111	2	0.01	-0.01-0.02	0.0	0.59	0.38	
		Sax	agliptin vs	metforr	nin					
Saxagliptin 5 mg QD	Metformin 2000 mg QD for 16 weeks	11	11	1	-0.06	-0.48-0.36	-	-	-	
Saxagliptin 5 mg QD	Metformin 2000 mg QD for 24 weeks	21	21	1	0.03	-0.01-0.07	-	-	-	
Overall: Saxagliptin vers	Overall: Saxagliptin versus Metformin 32		32	2	0.03	-0.01-0.07	0.0	0.67	0.15	
Saxagliptin vs saxagliptin+ metformin										
Saxagliptin 5 mg QD	Saxagliptin 5 mg QD with Metformin 2000	21	21	1	0.03	-0.01-0.07	-	-	-	

Overall: Saxagliptin versus Saxagliptin with Metformin		33	32	2	0.02	-0.02-0.05	9	0.30	0.34
Saxagliptin 5 mg QD	Saxagliptin 5 mg QD with Metformin 2000 mg QD for 16 weeks	12	11	1	-0.01	-0.07-0.05	-	-	-
	mg QD for 24 weeks								

RCT: randomised control trials, **I**²: heterogeneity, *The overall effect was significant at < 0.05, **CI**: confidence interval, **QD**: once a day, **BID**: Twice a day, **BMI**: body mass index, **WC**: waist circumference, **WHR**: waist to hip ration.